Skip to main content
Regulatory Notice 22-08

FINRA Reminds Members of Their Sales Practice Obligations for Complex Products and Options and Solicits Comment on Effective Practices and Rule Enhancements

Comment Period: May 9, 2022

The availability of complex products and options can potentially expand the investment opportunities for retail investors and, if properly understood, offer favorable investment outcomes (e.g., enhancing returns, limiting losses or improving diversification). However, important regulatory concerns arise when investors trade complex products without understanding their unique characteristics and risks. Like complex products, trading in options may pose risks if investors do not have the financial experience to understand options and options trading strategies. Therefore, we have taken steps to address complex products and options over the years, including publishing guidance regarding sales practice concerns raised by complex products and options; issuing investor-focused alerts to highlight the risks of these products; adopting rules with specific requirements for particular complex products and for options; and examining members for compliance with SEC and FINRA rules.

The number of accounts trading in complex products and options has increased significantly in recent years. As a result, we are again reminding members of their current regulatory obligations, including, as discussed below, the application of Regulation Best Interest (Reg BI) when broker-dealers and their associated persons make securities recommendations, and recommendations of investment strategies involving securities, to retail customers. In addition, we are soliciting comment on: (1) effective practices that members have developed for complex products and options, particularly when retail investors are involved; and (2) whether the current regulatory framework, which was adopted at a time when the majority of individuals accessed financial products through financial professionals, rather than through self-directed platforms, is appropriately tailored to address current concerns raised by complex products and options.1

Questions regarding this Notice should be directed to:

  • Meredith Cordisco, Associate General Counsel, Office of General Counsel, at (202) 728-8018;
  • Danny Mileto, Vice President, FINRA Market Regulation, at (212) 457-5323; or
  • Kathryn Moore, Senior Director & Counsel, FINRA Market Regulation, at (202) 728-8200.

Action Requested

FINRA encourages all interested parties to comment on this request for comment. Comments must be received by May 9, 2022.

Comments must be submitted through one of the following methods:

  • Online using FINRA's comment form for this Notice;
  • Emailing comments to [email protected]; or
  • Mailing comments in hard copy to:

Jennifer Piorko Mitchell
Office of the Corporate Secretary
FINRA
1735 K Street, NW
Washington, DC 20006-1506

To help FINRA process comments more efficiently, persons should use only one method to comment.

Important Notes: Comments received in response to Regulatory Notices will be made available to the public on the FINRA website. In general, comments will be posted as they are received.2

Before becoming effective, a proposed rule change must be approved by the FINRA Board of Governors and filed with the Securities and Exchange Commission (SEC) pursuant to Section 19(b) of the Securities Exchange Act of 1934 (SEA).3

Background & Discussion

What Is a Complex Product?

There is currently no standard definition of a “complex product.” Because new products and strategies are constantly introduced, FINRA has construed the term “complex product” flexibly to avoid a static definition that may not address the evolution of financial products and technology. In Regulatory Notice 12-03, FINRA described characteristics that would render a product “complex.”4

Specifically, FINRA has described a complex product as a product with features that may make it difficult for a retail investor to understand the essential characteristics of the product and its risks (including the payout structure and how the product may perform in different market and economic conditions). A product that combines features of multiple products and strategies also may be complex (e.g., leveraged or inverse exchange-traded products (ETPs)—collectively, “geared” ETPs—that can employ futures contracts and other derivatives or may engage in short sales; structured products with embedded optionality; interval funds; non-traded REITs).

Although FINRA refrained from defining “complex product” in Regulatory Notice 12-03, we provided numerous examples of the types of retail-oriented products that would be considered complex at that time, such as a variety of structured retail products (e.g., steepener notes and notes with worst-of features) and ETPs (e.g., geared and volatility-linked ETPs).5 We continue to believe that the features of these products are such that they may be difficult for a retail investor to understand the essential characteristics of the products and their risks and, are, therefore complex. In addition, since the publication of our guidance in Regulatory Notice 12-03, other types of products exist, or have recently emerged, that may be considered complex, including the following examples:

  • Defined outcome exchange-traded funds (ETFs) that offer structured retail product-type features, such as exposure to the performance of a market index or reference asset but with downside protection and an upside cap on potential gains over a specified period (typically one year). Unlike structured notes offering similar exposure but without an underlying portfolio, these defined outcome ETFs typically invest in exchange-listed options to provide the exposure. Similar to geared ETPs with a periodic exposure reset, defined outcome ETFs provide the specified outcome if an investor buys the ETF at the beginning of the period and holds it until the end. Otherwise, an investor’s returns could deviate significantly from the specified outcome.
  • Mutual funds and ETFs that offer strategies employing cryptocurrency futures.6 In addition to their exposure to cryptocurrency, which could itself be considered complex, these funds track futures contracts rather than the underlying cryptocurrency. Like other futures tracking products, such as commodity futures-linked ETPs, their performance may deviate considerably from that of the underlying asset. An additional potential layer of complexity may also relate to how these funds are structured and access the futures market (e.g., using a wholly-owned offshore subsidiary).7  
  • Interval funds, or tender-offer funds that provide limited liquidity to investors. Unlike traditional mutual funds, which in most situations allow investors to redeem 100 percent of their holdings in a specific fund at the next determined daily net asset value, these registered investment companies present complexities in the redemption process and in the amount of holdings available for redemption during a given period. Typically, investors can only exit an interval fund at certain intervals and the fund is only required to redeem five to 25 percent of its shares on a quarterly or sometimes less frequent basis, through a process where the fund “repurchases” shares from investors.8 Tender-offer fund repurchase offers are further subject to the discretion of the issuer’s board. As a result, investors may not be able to redeem all of their holdings during a repurchase window if the total amount of shares tendered by shareholders for repurchase exceeds the threshold set by the fund’s board for that repurchase window. In addition, shareholders must comply with the repurchase request deadline several weeks prior in order to redeem shares in the given period. Further, at the time an investor must commit to the repurchase process for an upcoming window, the investor will not know the price at which shares will be redeemed.9

These are examples only and are in no way meant to be exhaustive. 

Concerns Raised by Complex Products and Options

While many complex products serve a role in our financial markets, they also may raise a number of regulatory and investor protection concerns. For example, if a product has features or payout structures that would be confusing to retail investors, or if it performs in unexpected ways in various market or economic conditions, investors may not fully understand the attendant risks. Moreover, depending on how a complex product is structured, some may have built-in statutory protections while others may not, and this may not be clear to the investor.10 Although complex products do not always translate into more investment risk, their complexity may confuse investors who may not adequately understand their features. These concerns may be heightened when a retail customer is accessing these products through a self-directed platform and without the assistance of a financial professional, who may be in a position to explain the key features and risks of the product to the retail investor. 

In addition, as SEC Chair Gensler has recently suggested, complex products can potentially create system-wide risks by operating in unanticipated ways when markets experience volatility or stress conditions.11 Trading in complex products may also affect underlying assets. Thus, well-conceived protections in the sale and trading of complex products benefits market integrity in underlying markets.

Because of these concerns, complex products require careful member scrutiny and supervision. If financial professionals do not fully grasp the complex product’s features, they may engage in recommendations and sales that are not in the best interest of the customer. For example, in 2021, FINRA sanctioned:

  • a member that failed to reasonably supervise its brokers’ recommendations of leveraged, inverse and volatility-linked ETPs, leading to unsuitable recommendations of these products that caused customer losses;12
  • a member that failed to reasonably supervise a broker who recommended that numerous customers liquidate their retirement accounts and invest the proceeds in structured notes and other speculative and illiquid securities;13
  • a member that failed to reasonably supervise a broker who recommended that his customers—many of whom were seniors with conservative investment objectives—concentrate their accounts in a complex mortgage-backed security known as an inverse floating rate collateralized mortgage obligation (CMO), resulting in more than $2 million in customer losses;14 and
  • a broker who recommended concentrated investments in high-risk business development companies to customers (including customers over the age of 60), resulting in more than $1 million in losses.15

Similar to transactions in complex products, buying or selling options can be risky for retail investors who trade options without understanding their vocabulary,16 strategies and risks. Like the concerns associated with complex products, these concerns may be heightened when retail investors make self-directed decisions through online platforms without the assistance of a financial professional. Investors may use options strategies in a portfolio for a number of prudent reasons, including to hedge current positions17 and for income generation.18 Investors may also use options to speculate on the future price of a stock—whether up or down—and be able to do so by committing less funds up front than in buying or selling the underlying stock.19 However, options also have significant risks that investors may not always fully understand.20 Members should consider whether investors understand the various risks of trading options,21 including the following:

  • Options have risk driven by unexpected market movements. For uncovered call writers (sellers) there is risk of unlimited potential loss if the market rises sharply.22 For uncovered put writers (sellers), there is risk of losses if the market falls sharply. Excluding any premium collected, uncovered puts will typically incur a loss if the underlying closes below the strike price. Losses for uncovered puts reach a maximum when the stock price falls to or near zero.23
  • Investors purchasing puts and calls may not recoup any of their premium if the stock price fails to move as expected. There is risk of these investments becoming nearly worthless significantly prior to expiration if the market rises (for long puts) or falls (for long calls) sharply.
  • Options have risk driven by the time to expiration of the option. Options lose value over time and once the option expires “out of the money,” it is worthless. There is also a risk at expiration if the investor does not have the funds to exercise an in-the-money option.24
  • Options have risk driven by exercise provisions, such as exercise style.25
  • For writers (sellers) of options, the risks can include the assignment of the option.26

The above list is not exhaustive. Options and options strategies are routinely being developed and some risks are not apparent until there has been significant experience with them. 

To address concerns with options, FINRA’s options rule sets forth the approval process with which members must comply when opening a customer’s brokerage account for options, as well as the requirement of ongoing specific supervisory reviews for options accounts.27 FINRA enforces these and other applicable obligations and has sanctioned members and financial professionals for rule violations involving options. In 2020 and 2021, for example, FINRA sanctioned:

  • a broker who recommended an unsuitable options trading strategy to two retail customers, leading to more than $1.6 million in net losses;28
  • a broker who recommended that a retired customer in his 70s use funds in his retirement account to engage in an unsuitable options strategy, including selling uncovered or “naked” put options, resulting in more than $10,000 in losses;29 and
  • a member that provided false information to customers about the risks associated with options spread transactions, leading to more than $5 million in customer losses.30

FINRA’s Efforts to Address Complex Products and Options

Guidance

Over the years, FINRA has adopted rules and provided guidance to address the risks complex products and options pose. As noted above, we published Regulatory Notice 12-03 to broadly discuss complex products and provide guidance regarding, among others, compliance procedures for complex products. We emphasized that the complexity of a product often necessitates more member firm scrutiny and supervision, and we advised members to apply heightened supervision for complex products. We recommended that a member periodically assess complex products that the member offers to determine that their performance remains consistent with the manner in which the member is selling them, and provide comprehensive training for registered representatives that sell complex products. We also noted that, when recommending complex products to retail customers, members should consider whether a less complex product could achieve the same result. Significantly, we emphasized the importance of considering a customer’s financial sophistication to transact in complex products and encouraged members to employ an account opening approval approach, similar to that required for options, when considering an account to trade in complex products. 

We also have published numerous Regulatory Notices to address specific complex products, such as structured products,31 leveraged and inverse ETPs,32 principal protected notes,33 commodity futures-linked ETPs,34 reverse convertibles,35 volatility-linked ETPs36 and oil-linked ETPs.37 These Notices have focused on the particular risks related to the unique features of each of those products and have provided guidance urging members to adopt procedures for vetting such products and for supervising the sale and marketing of the products, particularly to retail investors. In 2021, moreover, we issued Regulatory Notice 21-15, reminding members of important steps a member must perform in connection with approving an investor to trade options, including, among others, that the member must perform due diligence on the customer and collect information about the customer to support a determination that options trading is appropriate for the customer regardless of whether the account is self-directed or advised.38 We reiterated that we view the “appropriateness” standard for approving accounts to trade in options as comparable to a suitability standard as used in Rule 2360(b)(19).39 We also reminded members that options accounts are subject to specific supervisory reviews, including reviewing the compatibility of options transactions with investment objectives and with the types of transactions for which the account was approved. 

In addition to issuing industry guidance, FINRA has released a number of publications providing important information about complex products, as well as options, directed specifically to retail investors.40

Product-Specific Rules

FINRA has developed a comprehensive framework of rules to address specific products, including options, security futures, direct participation programs (DPPs), deferred variable annuities (VAs), as well as index, currency index, and currency warrants. The rules governing options,41 security futures42 and warrants43 impose, among others, account opening requirements irrespective of whether a recommendation has been made; specific suitability requirements when recommending these products, including a reasonable belief that the customer has the knowledge and experience to evaluate the risks involved and the financial ability to bear these risks;44 specific principal registration and supervision requirements; position limits; exercise limits; reporting of positions to the Large Options Positions Reporting system; authority for FINRA to impose additional restrictions; disclosure, confirmation and account statement requirements; specific record-keeping requirements; and specific communications requirements.

The rule governing DPPs imposes specific procedures and factors to consider when recommending these products, restrictions on non-cash compensation paid in connection with the sale of these products, specific disclosures, and diligence where members participate in a public offering of DPP.45 The rules governing variable insurance contracts also impose specific procedures and factors to consider when recommending these products, restrictions on non-cash compensation paid in connection with the sale of these products and specific content standards for variable contract communications.46 They further impose specific requirements when recommending VAs, including principal review and approval obligations; specific written supervisory procedures reasonably designed to achieve compliance with the rule; and specific training requirements.47

We remind members to review their obligations under these product-specific rules, as well as under Reg BI, and to determine whether their policies and procedures continue to reflect the investor protection goals that these rules seek to achieve.

Strong Risk-Based Examination Program

Complementing this comprehensive regulatory framework, FINRA conducts risk-based examinations using a dynamic approach to identify potential problematic activity involving complex products and options. As we have repeatedly noted in our annual Report on FINRA’s Examination and Risk Monitoring Program, we regularly focus on members’ practices surrounding complex products and options.48 In general, our examinations review relevant communications and disclosures made to customers and use advanced analytics to review customer account activity to ensure that recommendations in these products are in the best interest of the retail customer given their investment profile and trading history. Our examinations also evaluate supervisory systems and controls members establish to mitigate risks, including with respect to these products and across various account types (e.g., self-directed accounts and those that are serviced by a financial professional). The evaluations may include assessments of the adequacy of related written supervisory procedures, the role of new or complex product committees, use of enhanced supervisory and compliance tools, including exception or activity reports, and any relevant training conducted by the member for their registered representatives and supervisors.

FINRA is in the process of conducting targeted examinations to review members’ practices and controls related to the opening of options accounts and related areas, including account supervision, communications and diligence.49 Although that work is ongoing, FINRA notes below a few themes that are arising as the review is underway:

  • Account Opening. Initial observations indicate potential gaps in identification of red flags in customer representations of trading experience, where members’ policies require minimum levels of experience for advanced level option accounts.
  • Disclosure Practices. Most members rely only on the delivery of “Characteristics and Risks of Standardized Options” (also known as the Options Disclosure Document or ODD) issued by the Options Clearing Corporation (OCC) to provide customers with information related to the risks of trading options,50 but there is a wide range of practices by members in the provision of educational materials in addition to the ODD specific to risks surrounding complex options transactions and the mechanics of options expiration.  
  • Options Exercise Procedures. FINRA staff also initially noted varying practices concerning cut-off times for customers to submit options exercise instructions. Specifically, FINRA’s options rule provides that option holders have until 5:30 p.m. Eastern Time (ET) on the business day of expiration to make a final decision to exercise or not exercise an expiring option.51 The rule also provides that members may set a time earlier than 5:30 p.m. ET by which customers must submit exercise instructions. In practice, FINRA found that members have set various early cut-off times and the communication of such cut-off times is not clear or consistently applied. A customer’s lack of knowledge of a member’s cut-off time for submission of contrary exercise decisions on expiration day may greatly impact the customer’s ability to profit from moves in the underlying security on which an option is based, due to after-market activity in those underlying instruments, or the ability to make an informed investment decision such as hedging against potentially significant losses.52

SEC’s Efforts Regarding Complex Products

Like FINRA, the SEC has long raised concerns with the risks complex products pose.53 Most recently, in October 2021, SEC Chair Gary Gensler directed SEC staff to study the risks of complex ETPs and to present recommendations for potential SEC rulemaking to address those risks.54 The SEC has also previously considered rulemaking to address complex products. For example, in 2015, the SEC requested comment on ETPs generally, noting their increased prevalence and soliciting comment regarding, among other things, the ways in which broker-dealers market ETPs, especially to retail investors and the extent to which individual investors understand the nature and operation of ETPs.55 

When adopting Reg BI, the SEC emphasized the importance of understanding the terms, features and risks of complex products, such as inverse and leveraged ETPs, in order to establish a reasonable basis to recommend these products to retail customers.56 The reasonable basis portion of Reg BI’s Care Obligation requires the broker-dealer or associated person to use reasonable diligence, care, and skill to understand the nature of the recommended security or investment strategy involving a security, as well as the potential risks, rewards and costs of the recommended security or investment strategy. It also requires a reasonable basis to believe that the recommendation could be in the best interest of at least some retail customers based on that understanding.57 Similar to FINRA’s suitability rule,58 a broker-dealer could violate the reasonable basis portion of Reg BI’s Care Obligation by not fully understanding the recommended security or investment strategy, even if the security or investment strategy could have been in the best interest of at least some retail customers.59 Reg BI and the fiduciary obligation of investment advisers as described in the 2019 Commission Interpretation Regarding Standard of Conduct for Investment Advisers suggest that firms apply heightened scrutiny when assessing whether recommendations of potentially high-risk products are in a retail customer’s best interest.60

In 2019 the SEC proposed sales practices rules that would require broker-dealers and SEC-registered investment advisers to exercise due diligence in approving a retail customer’s or client’s account to buy or sell shares of certain “leveraged/inverse investment vehicles” before accepting an order from, or placing an order for, the customer or client to engage in such transactions.61 Subsequent to that proposal, the SEC Chair and the directors of the Divisions of Investment Management, Corporation Finance and Trading and Markets published a Joint Statement Regarding Complex Financial Products and Retail Investors.62 The joint statement noted the SEC staff’s concern that retail investors are independently selecting complex products for which they may not fully appreciate the unique characteristics and risks. It stated that the SEC staff would review the effectiveness of the existing regulatory requirements in protecting investors—particularly those with self-directed accounts—who invest in leveraged/inverse products and other complex products, and recommend potential new rulemakings, guidance or other policy actions, if appropriate.

Further, the SEC’s Division of Examinations has noted that it will continue to focus on complex products in its examinations, including examining that broker-dealers are meeting their legal and compliance obligations when providing retail customers access to complex strategies, such as options trading and complex products.63 The SEC has also brought recent enforcement cases with respect to the sales of complex ETPs,64 and has issued follow-on guidance and numerous investor-focused publications focused on various complex products.65

Complex Products: Non-U.S. Jurisdictions

Regulators outside of the U.S. also have sought to strengthen investor protections surrounding the sale of complex products. For example, regulations and guidelines under the European Union’s (EU) Markets in Financial Instruments Directive (MiFID II) provide that firms should adopt robust and objective procedures, methodologies and tools to appropriately consider the different characteristics and relevant risk factors, including graduated levels of complexity, of each investment product they recommend, and match this with an investor’s information.66 For “non-advised” accounts trading complex products, MiFID II regulations require firms to assess the appropriateness of the investment and to issue a warning if the investor does not have the necessary knowledge and experience to understand the risks involved in relation to the specific investment service or product.67 To assist in the classification of complex products for purposes of assessing appropriateness, the European Securities and Markets Authority (ESMA) has issued guidelines specifying the criteria for the assessment of debt instruments and structured products, which incorporate structures, including embedded derivatives, that make it difficult for clients to understand the risks involved.68

Canadian securities regulators have recently enhanced their know-your-product suitability obligations and product due diligence guidance, through which firms can determine that a particular security may not be appropriate for retail investors or a subset of investors because it has complex or unique features that make it difficult for investors to fully understand.69 In addition, Canadian securities regulators recently issued guidance regarding order execution only accounts, noting that the limited ability for staff to directly handle orders eliminates an opportunity to identify potentially problematic orders or patterns prior to the entry of the order to a marketplace and stressing that dealer policies and procedures must be reasonably designed to ensure that dealers meet regulatory obligations to clients and to the market generally.70

Hong Kong’s regulators explicitly define complex products and provide minimum information and types of warning statements that must be provided to investors.71 Hong Kong’s regulators recently issued a circular to remind intermediaries of the requirements governing selling practices for insurance-linked securities, including suitability rules for complex products.72

Moreover, a growing number of financial regulators, including in the EU, Australia and the United Kingdom, have introduced product governance obligations to ensure product development is client focused and distribution is consistent with an identified target market for the product. Through product intervention rules, these foreign regulators also can prohibit or impose restrictions on the marketing, distribution or sale of certain financial products where a significant retail investor protection concern is determined to exist. Common restrictions include leverage limits, margin close-out requirements, standardized risk warnings, negative balance protection, and prohibitions on mass marketing and monetary incentives to clients.73

Increase in Trading in Complex Products and Options

While regulators have focused their efforts to address complex products and options, we remain concerned with the risks they pose, particularly when the data show that overall trading in complex products may be on the rise.

For example, the structured retail products market in the U.S. continues to see strong growth, with one commonly cited market data source indicating continued record volumes of products launched.74 Defined outcome ETFs, first launched in 2018, have grown to nearly 150 ETFs with almost $10 billion in market value, which is significant given their novelty and complexity in a very competitive market.75 Structured annuities, often referred to as registered index-linked annuities (RILAs), which also offer certain structured note-type exposures in an insurance vehicle, have seen rapid growth.76 While the number of geared ETPs and the market value they represent have remained fairly stable, some of these products are often among the most actively traded ETPs. It appears that retail investors continue to purchase these instruments.

Similarly, listed options trading volume has grown to over 38.6 million contracts a day on average, more than 30 percent higher than the 29.5 million contracts traded per day in 2020 and almost 100 percent higher than the 19.8 million contracts per day traded in 2019.77 Although the volume of trading in these products has significantly changed, the core rules governing options accounts, which are uniform across the options exchanges and FINRA,78 have remained largely unchanged since they were put in place following an SEC study of oversight of the options markets in 1978.79 At that time, an investor could only transact in options through contact with a registered professional and on a limited number of exchange floors. Today, after being approved for options, self-directed investors can actively trade online through multiple exchanges without engaging with individuals or seeking professional advice.

In light of the continued concerns regarding complex products and options, accompanied by the increased activity in complex products and options and evolving retail customer access, FINRA is soliciting comment on effective practices that members have developed for managing the risks complex products and options raise, particularly those accessible to self-directed retail investors, and whether the current regulatory framework is appropriately tailored to address the concerns complex products and options raise.

Request for Comment

Complex Products

  1. How do members categorize products as “complex”? Have firms implemented categories or tiers of complex products and, if so, how have firms determined such tiers? What types of products have recently been introduced that should be viewed as complex? Does our description of characteristics that render a product “complex” continue to appropriately cover necessary products?
     
  2. What practices have firms developed and implemented that have proved effective with respect to supervising sales and trading of complex products, including in self-directed accounts? For example, have members implemented and, if so found effective, any of the following measures with respect to complex products: 
     
    1. Enhanced account approval processes before an account may trade in complex products?
    2. Requirements that a customer complete training or a learning course before approval to trade in certain complex products?
    3. Additional disclosures or educational materials on complex products?
    4. Required customer attestations regarding knowledge and experience?
    5. Restrictions or limitations on retail customer access to complex products (e.g., limiting access to high-net worth or other categories of customers)?
       
  3. What specific supervisory practices that enhance members’ review of a customer’s transactions in complex products, including transactions in self-directed accounts, have proved effective?
     
  4. What are effective practices by members for reviewing advertising with respect to complex products? 
     
  5. How do members assess financial professionals’ understanding of specific products?
     
  6. Should any of the current product-specific requirements (e.g., account opening requirements irrespective of whether a recommendation has been made; specific standard of care requirements when recommending these products; specific principal registration and supervision requirements; position limits; exercise limits; disclosure, confirmation and account statement requirements; or specific record-keeping requirements) apply more generally to complex products?
     
  7. Should different or additional requirements be applied with respect to complex products? For example, regardless of whether a recommendation has been made, should FINRA:
     
    1. Require members to make a reasonable assessment of whether a product is “complex” before allowing a retail customer to transact in the product?
    2. Require members to implement an account approval process before the retail customer’s account may transact in any product that the firm has reasonably assessed to be complex? If so, should that process be modeled on FINRA’s options rule account approval process or a different process? Please explain.
    3. Impose other obligations before the retail customer’s account may be approved to transact in complex products, such as requiring:
      1. The member to provide the retail customer with general, plain language, educational materials about the common characteristics and risks of complex products?
      2. Retail customers to demonstrate their understanding of those common characteristics and risks of complex products by completing a knowledge check and, if the customer fails to show the requisite knowledge, requiring the completion of a learning course and additional assessment?
      3. Principal approval for a retail customer account to transact in complex products?
    4. Once a retail customer’s account is approved generally for complex products, should continuous or periodic obligations apply, such as:
      1. Before transacting in any particular complex product, or periodically while the customer holds the complex product, requiring retail customers to review disclosures regarding the characteristics and risks of the specific product and attest that they have read and understand them?
      2. Requiring members to periodically reassess the retail customer’s account to ensure that the initial account approval remains appropriate
    5. Would the aforementioned obligations unduly or appropriately restrict investor access to complex products?
    6. Should comparable standards apply to other investment intermediaries, such as investment advisers or insurance agencies, that provide access to or recommend to individual customers transactions in complex products?
       
  8. Should targeted communications, such as push notifications to self-directed retail customers regarding complex products, be subject to specific restrictions? For example, should they be restricted unless certain conditions have been satisfied, including that the account has been approved for complex products?
     
  9. In addition to applicable requirements in FINRA Rule 2210 (Communications with the Public), should members be required to file communications that promote or recommend complex products with the Advertising Regulation Department of FINRA for review before their first use?
     
  10. Should additional supervisory obligations apply with respect to complex products and retail customers, such as requiring members to implement:
     
    1. Heightened supervision for recommendations of complex products to retail customers?
    2. Policies and procedures to help ensure that retail customers possess the requisite understanding of the complex product and its risk prior to allowing such investment, including in self-directed accounts?
    3. Testing relating to the implementation of those policies and procedures, including the testing of automated systems that are used as part of that implementation process?
       
  11. Are there regulatory developments in other jurisdictions related to complex products that would strengthen protections regarding complex products, including in self-directed accounts? For example, to address the risk of customer overestimating their knowledge and experience, should members be required to implement:
     
    1. Procedures designed to limit a customer’s possible circumvention of questionnaires such as a cooling-off period before a customer can respond more than once to a questionnaire designed to assess their level of knowledge?
    2. Tools to counterbalance self-assessments with objective criteria?
    3. In the case of online services, design features to ensure information and questionnaires are sufficiently clear?
       
  12. Given the uptick in transactions in options and other complex products through self-directed platforms, many of which are designed to provide retail customers with easy access to an array of financial products, are additional guardrails needed for these types of platforms, including for example, in cases where communications through the platform do not rise to the level of a “recommendation” under Reg BI?80

Options

  1. What practices have proved effective with respect to compliance with the options requirements, including supervision, disclosure and account approval requirements?
     
  2. Are there additional requirements that should be added to the existing options requirements? For example:
     
    1. Current SRO options rules (e.g., FINRA Rule 2360(b)(16)) require that a member must approve a customer to trade options and requires the member to exercise due diligence to ascertain the essential facts relative to the customer to determine if it is appropriate to approve the customer to trade options. Members have implemented this requirement in varying ways. Many members have developed a system of options “levels” ranging from less risky options and strategies to more risky options strategies based on the customer’s risk tolerance, investing experience and upon the customer opening a margin account. Members also have developed processes to determine when a customer may “move up” to the next level of options trading. Should specific standards apply for the kinds of options and strategies that are permitted at a given level and standards for a customer to be approved for each level? 
       
      1. What kind of options should be permitted for each level?
      2. What should the standards be to approve a customer for each level?
      3. Should members be required to make a suitability determination for each level regardless of whether the account is recommended or self-directed? 
      4. Should members be required to make a determination whether a customer should be permitted to use margin for each option level where margin is required, regardless of whether the account is recommended or self-directed?
      5. Should members be expected to provide specified information and customers to meet specified objective criteria, such as having a certain number of years of trading experience or having a specific amount of equity in their account prior to trading options? Should members be required to provide additional information and for customers to meet additional objective criteria (for example a higher level of equity or more years of trading experience) as the level of options trading increases? If so, what information should a member be required to provide and what information should a member obtain in order to determine if the account is appropriate to trade options?
         
    2. Should members be required to have a conversation with each customer, regardless of whether an account is self-directed or options are being recommended, prior to approval to trade options to ensure that it is appropriate to approve the customer to trade options? How would this best be implemented for a customer who has an online account?
       
    3. Should periodic reassessment of the retail customer’s account be required to ensure that the initial account approval for options trading remains appropriate?
       
    4. Should targeted communications, such as push notifications to self-directed retail customers, regarding options be subject to specific restrictions? For example, should they be restricted unless certain conditions have been satisfied, including, for example, that the account has been approved for options?
       
    5. Currently, Rule 2220(c)(1) requires that all retail communications issued by a member concerning standardized options used prior to delivery of the applicable current options disclosure document or prospectus be submitted to the Advertising Regulation Department of FINRA at least ten calendar days prior to use. Should members be required to file all retail communications that promote or recommend options or options strategies prior to use?
       
    6. Should members be required to provide customers specific educational or training materials in addition to what is already required before a customer, including a self-directed customer, may be approved to trade options? 
      1. After receiving additional education or training, should customers be required to demonstrate to the member the customer’s understanding about options? What form of demonstration would be most efficient and effective? Should the demonstration include answering questions or otherwise demonstrating understanding of options?
      2. SRO options rules (e.g., FINRA Rule 2360(b)(16)) require that a member give a customer the Options Disclosure Document81 prior to approval for options trading.  Should a simple, perhaps single page, disclosure document that focuses on the key risks of trading options be required to be delivered, in addition to the ODD, to a customer prior to approval for options trading?
         
        1. What are the key risks that should be communicated other than those set forth in the ODD?
        2. Should members also receive an acknowledgement of understanding of the risks of trading options from customers before approving a customer to trade options? Should this requirement to acknowledge an understanding of the risks of trading options be required to be completed every year?
           
    7. Should members be required to display total position risk for retail customers holding positions in options, or holding positions that have been entered into as the result of an options assignment? For example, where a customer holds positions in both an option and the underlying instrument, or in multiple options on the same security, such that the exercise of an option may act to limit overall risk, should members display the maximum potential loss and gain for each underlying asset based on their combined option and underlying exposure?
       
    8. SRO options rules (e.g., FINRA Rule 2360(b)(20)) detail the supervisory requirements for options, as we explained in Regulatory Notice 21-15. Should members conduct heightened or more frequent supervisory review after they have approved a customer, including a self-directed customer, to trade options? What form of heightened supervisory review would be most efficient and effective? If distinct from heightened supervisory review, what form of frequent supervisory review would be most efficient and effective? How often should the review occur?
       
    9. If in reviewing an account, a member identifies that a customer has entered into an options transaction (such as a spread traded above parity82) whereby it is impossible for the customer to profit from the transaction, should the member be required to pause or suspend the customer from further transacting in options or certain kinds of options? 
       
    10. SRO options rules (e.g., FINRA Rule 2360(b)(23)) provide that option holders have until 5:30 p.m. ET on the business day of expiration, or, in the case of a standardized equity option expiring on a day that is not a business day, on the business day immediately prior to the expiration date to make a final decision to exercise or not exercise an expiring option. Members may not accept exercise instructions after 5:30 p.m. ET.  However, members may establish fixed procedures as to the latest time they will accept exercise instructions from customers. Some members have set a deadline for customers to make an exercise decision prior to 5:30 p.m. ET deadline, for example by 4:00 p.m. ET. Should all members give investors to 5:30 p.m. ET to make a final exercise decision?

    11. Would any of the aforementioned obligations unduly or appropriately restrict investor access to options?
       
  3. Should comparable standards apply to other investment intermediaries, such as investment advisers or insurance agencies, that provide access to or recommend to individual customers transactions in options?

Endnotes


1SEC Chair Gary Gensler has directed the SEC to study this area and recommend changes, if appropriate. See, SEC Chair Gary Gensler, Statement on Complex Exchange-Traded Products (Oct. 4, 2021) (hereinafter Gensler Statement on Complex Products). FINRA intends to coordinate its response to this request for comment with the SEC’s development of its regulatory approach to this topic.

2Parties should submit in their comments only personally identifiable information, such as phone numbers and addresses, that they wish to make available publicly. FINRA, however, reserves the right to redact or edit personally identifiable information from comment submissions. FINRA also reserves the right to redact, remove or decline to post comments that are inappropriate for publication, such as vulgar, abusive or potentially fraudulent comment letters.

3See SEA Section 19 and rules thereunder. After a proposed rule change is filed with the SEC, the proposed rule change generally is published for public comment in the Federal Register. Certain limited types of proposed rule changes take effect upon filing with the SEC. See SEA Section 19(b)(3) and SEA Rule 19b-4.

4See Regulatory Notice 12-03 (Complex Products, Heightened Supervision of Complex Products) (Jan. 2012). 

5See id. Some industry participants have advocated for an ETP classification system that would identify and categorize certain ETPs with complex structures or embedded risks as exchange-traded notes (ETNs), exchange-traded commodities (ETCs) or exchange-traded instruments (ETIs), rather than as exchange-traded funds (ETFs). See, e.g., Blackrock comment in response to SEC Joint Statement Regarding Complex Financial Products and Retail Investors (Apr. 14, 2021).

6Beyond these products and exchange-listed futures on related crypto assets, retail investors seeking exposure to crypto assets (outside of directly owning them) may have alternatives through, for example, over-the-counter securities in the form of investment trusts holding a crypto asset. However, such products may present further complexities in terms of how they are structured as well as being potentially less liquid and having performance that can diverge from that of the underlying crypto asset.

7The first Bitcoin Futures ETF, which the SEC declined to block, began trading on the NYSE on October 20, 2021. Options on this ETF were listed shortly after. A second was launched on October 22, 2021. The first mutual fund focused on Bitcoin Futures was launched in July 2021.

8See, e.g., FINRA Investor Alert, Interval Funds – 6 Things to Know Before You Invest (Jan. 23, 2018). 

9See e.g., SEC Investor Bulletin: Interval Funds (Sept. 25, 2020).

10For example, some ETPs are registered as investment companies under the Investment Company Act of 1940 and are subject to its protections. On the other hand, other complex products, such as exchange-traded notes, structured notes, and commodity pools are structured differently and, regardless of their relative complexity or risk, are not subject to the requirements of the Investment Company Act. 

11See Gensler Statement on Complex Products (referencing the SEC’s Asset Management Advisory Committee’s recommendations to the SEC and FINRA designed to improve the ETP ecosystem, Preliminary Recommendations of ETP Panel Regarding COVID-19 Volatility: Exchange-Traded Products, Asset Management Advisory Committee (Sept. 16, 2020)). 

12See Calton & Associates, Inc., AWC No. 2018060466201 (May 17, 2021).

13See Independent Financial Group, LLC, AWC No. 2018059223401 (Apr. 8, 2021).

14See American Independent Securities Group, LLC, AWC No. 2018060267902 (March 29, 2021).

15See Kevin Marshall McCallum, AWC No.  2019062569501 (June 17, 2021).

16See FINRA Investor Insights, Options A-Z: The Basics to the Greeks, regarding options terminology (June 4, 2015).

17For example, an investor may hedge with a protective put option to limit losses on downward movement of the underlying stock that is owned by the investor. The investor could purchase a put option at a strike price below the current price of the stock. If the price of the stock falls below the strike price of the option, the investor can exercise the put option and sell their shares at the strike instead of the current market price. This strategy could limit the impact to a position when the stock price falls.

18For example, an investor may engage in covered call writing whereby an investor can write (sell) a call option on a stock the investor owns to earn the options premium. 

19For example, an investor may purchase a $12 call option, for a total investment of $1200, overlying a stock that is valued at $60 per share, which provides some exposure to the price movement in the underlying stock for less than the cost of buying 100 shares at $60 ($6,000). One option contract typically covers 100 shares of underlying stock. 

20See Characteristics and Risks of Standardized Options (also known as the Options Disclosure Documents or “ODD”) (Oct. 2021) for more detailed description of risks with options.    

21In addition, Reg BI requires members who make recommendations, including recommendations to trade in options, to open an options account, or to engage in an investment strategy involving options, to, among other things, have a reasonable basis to believe that the recommendation is in the best interest of a particular retail customer based on that customer’s investment profile and the potential risks, rewards and costs associated with the recommendation.

22When the investor does not own the offsetting position in the underlying security, the investor may have to acquire the security if the price of the underlying security rises and the buyer of the option seeks to exercise it. The maximum loss could be unlimited as there is no cap on how high the price of the underlying security can rise.

23For example, if an investor sells a put option with a strike price of $50 and the underlying security falls to $1 at expiration, the investor should expect to be assigned on their put, thereby purchasing 100 shares at $50 for a total of $5,000. While the value of the position would be $100 based on current share price ($1 per share), the investor would have an unrealized loss of $4,900, excluding the premium received.

24Listed equity options are settled with physical delivery of the underlying security, not cash settled. For example, if an investor purchases a call option in a cash account with a strike price of $50 and the underlying security is trading at $60 per share at expiration, the investor should not expect a “payout” of $1,000 for the price difference between the strike price and the closing price at expiration. Instead, the investor must have $5,000 in order to purchase the shares at expiration based on the strike price. While the value of the position would be $6,000 based on current shares price ($60 per share), the investor would have an unrealized gain of $1,000. Alternatively, the investor could sell the option on expiration, which may not necessarily maximize the potential gains.

25The options contract will specify when the option may be exercised. European-style options provide the option may only be exercised on its expiration date while American-style options may be exercised at any point during the life of the contract. Option holders must be sure to understand the exercise provisions and exercise mechanics. See also Information Notice 2/3/21 (Exercise Cut-Off Time for Expiring Options).

26See FINRA and OCC Staff Investor Insights: Trading Options: Understanding Assignment, infra note 40, regarding assignment which is the seller’s obligation to fulfill the terms of the contract by either selling or buying the underlying security at the exercise price.

27See Rule 2360(b)(16) and FINRA Rule 2360(b)(20), respectively.

28See Cesar Hurtado, AWC No. 20170558909 (Aug. 6, 2021).

29See Mason Gann, AWC No. 20180574252 (Jan. 27, 2020).

30See Robinhood Financial LLC, AWC No. 2020066971201 (June 30, 2021).

31See Notice to Members 05-59 (NASD Provides Guidance Concerning the Sale of Structured Products) (Sept. 2005).

32See Regulatory Notice 09-31 (June 2009).

33See Regulatory Notice 09-73 (Dec. 2009).

34See Regulatory Notice 10-51 (Oct. 2010).

35See Regulatory Notice 10-09 (Feb. 2010).

36See Regulatory Notice 17-32 (Oct. 2017).

37See Regulatory Notice 20-14 (May 2020).

38See Regulatory Notice 21-15 (April 2021). 

39See id. at n.7 (noting that, in the context of evaluating customer information for the purposes of approving a customer to trade options, FINRA views the options trading approval standard, which is expressed as appropriateness in Notice to Members 80-23, as comparable to a suitability standard as used in Rule 2360(b)(19)).

40FINRA has issued a number of investor-focused publications on complex products and options (e.g., FINRA Investor Insight: Know Before You Invest: Volatility-Linked Exchange-Traded Products (October 26, 2017); FINRA Investor Insights: The Lowdown on Leveraged and Inverse Exchange-Traded Products (Nov. 22, 2016); Investor Alert: Alternative Funds Are Not Your Typical Mutual Funds (June 11, 2013); Investor Alert: Exchange-Traded Notes—Avoid Unpleasant Surprises (July 10, 2012); Investor Alert: Structured Notes With Principal Protection (June 2, 2011); Investor Alert: Reverse Convertibles: Complex Investment Vehicles (July 29, 2011); Investor Insights, Options A-Z: The Basics to The Greeks (June 4, 2015); FINRA and OCC Staff Investor Insights: Trading Options: Understanding Assignment (Dec. 14, 2020).

41See FINRA Rule 2360 (Options); FINRA Rule 2220 (Options Communications).

42See FINRA Rule 2370 (Security Futures); FINRA Rule 2215 (Communications with the Public Regarding Security Futures).

43See FINRA Rule 2350 Series (Trading in Index Warrants, Currency Index Warrants and Currency Warrants).

44Reg BI would also apply to the extent that a broker-dealer or associated person recommends such a product, or an investment strategy involving the product, to a retail customer.

45See FINRA Rule 2310 (Direct Participation Programs).

46See FINRA Rule 2211 (Communications with the Public About Variable Life Insurance and Variable Annuities); FINRA Rule 2320 (Variable Contracts of an Insurance Company); and FINRA Rule 2330 (Members’ Responsibilities Regarding Deferred Variable Annuities).

47See FINRA Rule 2330. As noted above, Reg BI would also apply to the extent that a broker-dealer or associated person recommends a VA to a retail customer.

48See, e.g., 2022 Report on FINRA’s Examination and Risk Monitoring Program (Feb. 9, 2022), (“FINRA will continue to review firms’ communications and disclosures made to customers in relation to complex products, and will review customer account activity to assess whether firms’ recommendations regarding these products are in the best interest of the retail customer given their investment profile and the potential risks, rewards and costs associated with the recommendation.”).

50See supra note 20.

51See Rule 2360(b)(23).

52See e.g., FINRA and OCC Staff Investor Insights: Trading Options: Understanding Assignment (Dec. 14, 2020), supra note 40.

53In addition to complex products, and of historic significance, at the advent of the computerized brokerage systems, the SEC issued guidance regarding potential investor protection risks posed by such systems and emphasizing broker-dealer obligations, particularly in the case of risky investments. See Notice of Commission Views on Computer Brokerage Systems, Securities Exchange Act Release No. 21383 (October 9, 1984), 49 FR 40159, 40161 (October 15, 1984) (“Because these systems provide investors greater flexibility in trading, the Commission believes it is important that a broker-dealer use a high degree of care in making its initial determination regarding an investor’s financial qualifications and his suitability for large and risky investments.”).

54See Gensler Statement on Complex Products. Commissioners Allison Lee and Caroline A. Crenshaw also issued a joint Statement on Complex Exchange-Traded Products, noting the significant investor protection issues and potential systemic risks raised by the sale of complex ETPs, recommending that the Commission update the rules for these products, and outlining principles that should apply to an updated regulatory framework. See Commissioners Lee and Crenshaw, Statement on Complex Exchange-Traded Products (Oct. 4, 2021).

55See SEC Request for Comment on Exchange-Traded Products, Securities Exchange Act Release No. 75165 (June 12, 2015), 80 FR 34729, 34742 (June 17, 2015).

56See Regulation Best Interest, Securities Exchange Act Release No. 86031 (June 5, 2019), 84 FR 33318 (July 12, 2019) (Reg BI Adopting Release).

57See Regulation Best Interest, Securities Exchange Act Rule 15l-1(a)(2)(ii)(A).

58FINRA’s suitability rule (FINRA Rule 2111) applies to recommendations that are not covered by Reg BI (i.e., recommendations to non-retail customers). See Rule 2111.08.

59See Reg BI Adopting Release, 84 FR at 33376.

60See Reg BI Adopting Release at 33376. Note that Reg BI and FINRA Rule 2111 apply when a broker-dealer or its associated persons make securities recommendations (including, in the case of Reg BI, recommendations of types of accounts); neither Reg BI nor Rule 2111 apply in the absence of a recommendation, such as where a retail investor invests entirely on their own accord in complex products through a self-directed account. See also Commission Interpretation Regarding Standard of Conduct for Investment Advisers, Investment Act Release No. 5248 (June 5, 2019), 84 FR 33669, 33673-74 (July 12, 2019).

61See SEC Proposed Rule, Use of Derivatives by Registered Investment Companies and Business Development Companies; Required Due Diligence by Broker-Dealers and Registered Investment Advisers Regarding Retail Customers’ Transactions in Certain Leveraged/Inverse Investment Vehicles, Securities Exchange Act Release No. 87607 (November 25, 2019), 85 FR 4446 (January 24, 2020).

62See U.S. Securities and Exchange Commission, Joint Statement Regarding Complex Financial Products and Retail Investors (Oct. 28, 2020).

63See SEC Division of Examinations, 2021 Examination Priorities, (March 3, 2021).

64See SEC press release, SEC Charges Investment Advisory Firms and Broker-Dealers in Connection with Sales of Complex Exchange-Traded Products (Nov. 13, 2020); see also SEC Division of Examinations Public Statement on Recent Enforcement Matters Involving “VIX-Related” and Other Complex Exchange Traded Products (ETPs) (Nov. 16, 2020). 

65The SEC’s Office of Investor Education and Advocacy has published numerous Investor Bulletins on complex products in recent years. See, e.g., Investor Bulletin: Leveraged Investing Strategies – Know the Risks Before Using These Advanced Investment Tools (June 10, 2021); Updated Investor Bulletin: Indexed Annuities (July 31, 2020); Leveraged Loan Funds – Investor Bulletin (Nov. 20, 2019); Updated Investor Bulletin: Variable Annuities (Oct. 30, 2018); Investor Bulletin: Exchange Traded Notes (ETNs) (Dec. 1, 2015); Investor Bulletin: An Introduction to Options (March 18, 2015) and Investor Bulletin: Opening an Options Account (March 18, 2015).

66See European Securities and Markets Authority (ESMA), Guidelines on Certain Aspects of the MiFID II Suitability Requirements, (paragraphs 69-87) (June 11, 2018). 

67See MiFID II Articles 25(3)-(4) and MiFID II Delegated Regulation Articles 55-57. See also ESMA, Guidelines on Certain Aspects of the MiFID II Appropriateness and Execution-Only Requirements (Jan. 3, 2022).

68See ESMA, Guidelines on Complex Debt Instruments and Structured Deposits (Feb. 4, 2016). See also ESMA, Guidelines on Certain Aspects of the MiFID II Appropriateness and Execution-Only Requirements, supra note 67.

69See The Ontario Securities Commission, Reforms to Enhance the Client-Registrant Relationship (Client Focused Reforms), Vol. 42, Issue 40 (Oct. 3, 2019); see also Investment Industry Regulatory Organization of Canada (IIROC) Notice GN-3300-21-001, Guidance Note on Product Due Diligence and Know-Your-Product (Dec. 31, 2021).

70See IIROC Notice GN-3200-21-002, Guidance Respecting Order Execution Only Accounts as a Form of Third-Party Electronic Access to Marketplaces (Oct. 14, 2021).

71See Hong Kong Securities and Futures Commission, Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (SFC), art. 5.5 (2020); see also SFC, Guidelines on Online Distribution and Advisory Platforms, ch. 6 (July 2019); see also SFC, Minimum information to be provided and warning statements (June 12, 2019). 

72 See Hong Kong Monetary Authority and Hong Kong Securities and Futures Commission, Circular to Intermediaries: Distribution of Insurance-Linked Securities and Related Products (Oct. 11, 2021) . These requirements include product due diligence, taking into account factors such as the products’ nature, features, risks, any restrictions on the sale of the products and target investors, and suitability; ensuring that the risk/return profile of the product matches the financial situation, objectives, experience, risk tolerance, and other circumstances of the client; providing sufficient and accurate product information to clients, as well as clear and prominent warning statements; and staff training on products and how to disclose their nature, features and risks to clients.

73Some examples where product intervention powers have been used include binary options and contracts for difference (e.g., ESMA, most of the EU National Authorities, UK FCA, and Australian Securities and Investments Commission (ASIC)); turbos/a type of leveraged product (Dutch Financial Markets Authority); crypto-asset derivatives (UK FCA); crypto-asset exchange traded notes (UK FCA); contingent convertible instruments and CoCo funds (UK FCA); and mini-bonds (UK FCA). European Securities and Markets Authority—Product Intervention (provides list of interventions by ESMA and the National Competent Authorities). See FCA Handbook, Conduct of Business Sourcebook, COBS 4.14,  22.3-22.6; ASIC Corporations (Product Intervention Order—Binary Options) Instrument 2021/240 (Apr. 1, 2021).

75See Allan Roth, Are Defined Outcome ETFs For You? (Oct. 6, 2021).

76See Lavanya Nair, US Insurance Regulator Concerned with Rila Growth, (Oct. 19, 2021).

77See Options Clearing Corporation data. Data for 2021 includes trade dates between January 1 and October 15, 2021.

78 See, e.g., Cboe Rules 9.1-9.9 and Nasdaq Rules Option 10, Section 6 – 10, 13.

79See Report of the Special Study of the Options Markets to the Securities and Exchange Commission, 96th Cong., 1st Sess. (Comm. Print No. 96-IFC3, December 22, 1978).  After the approval of Cboe as the first options exchange, the SEC released a report on the efficacy of SRO and SEC oversight of the burgeoning options markets. The study called for close cooperation among the SROs and the SEC, and recommended several specific actions designed to correct the deficiencies found by the SEC in surveillance and sales practices. These recommendations led to the uniform options conduct rules adopted by the SROs.

80The SEC’s Digital Engagement Practices (DEPs) request for comment addresses DEPs and Reg BI, including how broker-dealers consider the impact of DEPs when determining whether recommendations are made for purposes of Reg BI. See Securities Exchange Act Release No. 92766 (August 27, 2021), 86 FR 49067 (September 1, 2021) (Request for Information and Comments on Broker-Dealer and Investment Adviser Digital Engagement Practices, Related Tools and Methods, and Regulatory Considerations and Potential Approaches; Information and Comments on Investment Adviser Use of Technology To Develop and Provide Investment Advice). As noted above, FINRA intends to coordinate its response to this request for comment with the Commission’s development of its regulatory approach. 

81See supra note 20.

82For example, if the investor enters into an option spread transaction whereby the premium exceeds the maximum potential profit. 

The views, expressions, findings and opinions expressed in the comments on this Web page are solely those of the author(s) and FINRA accepts no responsibility for the content of the comments:
Date Commenter
Anonymous Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Nick Lafferty Comment On Regulatory Notice 22-08
Bernard Jentner Comment On Regulatory Notice 22-08
Mohammad Iqbal Comment On Regulatory Notice 22-08
Lindsay Ash Comment On Regulatory Notice 22-08
Ralph W Atteberry Comment On Regulatory Notice 22-08
Retail Investor Comment On Regulatory Notice 22-08
Kendon Brown Comment On Regulatory Notice 22-08
J Chimni Comment On Regulatory Notice 22-08
Devon Jones Comment On Regulatory Notice 22-08
G Singh Comment On Regulatory Notice 22-08
Sean Roberts Comment On Regulatory Notice 22-08
Bryon Mangler Comment On Regulatory Notice 22-08
Sami Rasheed Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Evan Davis Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
James Landry Comment On Regulatory Notice 22-08
Chris Olson Comment On Regulatory Notice 22-08
Grant Lincoln Comment On Regulatory Notice 22-08
Danielle Douglas Comment On Regulatory Notice 22-08
Justin Comment On Regulatory Notice 22-08
Brian Lellis Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Joel T. Giedt Comment On Regulatory Notice 22-08
Logan Comment On Regulatory Notice 22-08
C. Young Comment On Regulatory Notice 22-08
Matthew Rollins Comment On Regulatory Notice 22-08
Adrian Meraz Comment On Regulatory Notice 22-08
Ram Kumar Comment On Regulatory Notice 22-08
Joseph Mcdermott Comment On Regulatory Notice 22-08
Bobby Comment On Regulatory Notice 22-08
Dylan Huggins Comment On Regulatory Notice 22-08
Daniel Reich Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Brett S Comment On Regulatory Notice 22-08
Michael B. Comment On Regulatory Notice 22-08
Louis Straney Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Phil Bak Comments On Regulatory Notice 22-08
E.J.R.W. Comment On Regulatory Notice 22-08
Dave Nadig Comment On Regulatory Notice 22-08
Sean Kniznik Comment On Regulatory Notice 22-08
John L Comment On Regulatory Notice 22-08
Eliajah Hunsaker Comment On Regulatory Notice 22-08
Francesco Franzoni Comment On Regulatory Notice 22-08
Van Eck Securities Corporation Comment On Regulatory Notice 22-08
Fred Beisse Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Digital Assets Council of Financial Professionals and The Truth About Your Future LLC Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Richard Howe Comment On Regulatory Notice 22-08
Alexander Frederick Comment On Regulatory Notice 22-08
David Lubert Comment On Regulatory Notice 22-08
Jonathan Mcgill Comment On Regulatory Notice 22-08
David Brown Comment On Regulatory Notice 22-08
Linda Raper Comment On Regulatory Notice 22-08
David Boone Comment On Regulatory Notice 22-08
Richard Edly Comment On Regulatory Notice 22-08
Gary McClung Comment On Regulatory Notice 22-08
Matthew Sissung Comment On Regulatory Notice 22-08
Ian Lamb Comment On Regulatory Notice 22-08
Scott Kister Comment On Regulatory Notice 22-08
William Gerry Comment On Regulatory Notice 22-08
Terence Riley Comment On Regulatory Notice 22-08
Joseph OConnell Comment On Regulatory Notice 22-08
Donald Mullin Comment On Regulatory Notice 22-08
Joyce Dugger Comment On Regulatory Notice 22-08
Priya Shah Comment On Regulatory Notice 22-08
James Bowers Comment On Regulatory Notice 22-08
Thomas Alexander Comment On Regulatory Notice 22-08
Ruben Velarde Comment On Regulatory Notice 22-08
James Carlin Comment On Regulatory Notice 22-08
Robert Minkus Comment On Regulatory Notice 22-08
Stephen Hazlett Comment On Regulatory Notice 22-08
Allen Brock Comment On Regulatory Notice 22-08
Chase Henson Comment On Regulatory Notice 22-08
Sean Gissal Comment On Regulatory Notice 22-08
Kevin Allen Comment On Regulatory Notice 22-08
James Miller Comment On Regulatory Notice 22-08
Karen Hunt Comment On Regulatory Notice 22-08
Bradley Winter Comment On Regulatory Notice 22-08
Kelly Snellenbarger Comment On Regulatory Notice 22-08
Brian Eby Comment On Regulatory Notice 22-08
Joe Hage Comment On Regulatory Notice 22-08
Benjamin Ammon Comment On Regulatory Notice 22-08
Vijay Rajan Comment On Regulatory Notice 22-08
Matthew Lenton Comment On Regulatory Notice 22-08
Jim Dresser Comment On Regulatory Notice 22-08
Dow Hickam Comment On Regulatory Notice 22-08
Shirish Patrawalla Comment On Regulatory Notice 22-08
Michael Pyle Comment On Regulatory Notice 22-08
Avner Rietti Comment On Regulatory Notice 22-08
Alan Reid Comment On Regulatory Notice 22-08
Richard Klein Comment On Regulatory Notice 22-08
Jane Harris Comment On Regulatory Notice 22-08
Kartik Chandar Comment On Regulatory Notice 22-08
Greg Bassett Comment On Regulatory Notice 22-08
Jay Yelas Comment On Regulatory Notice 22-08
Robert Lawson Comment On Regulatory Notice 22-08
Gordon Martin Comment On Regulatory Notice 22-08
Cory Melick Comment On Regulatory Notice 22-08
David Self Comment On Regulatory Notice 22-08
Edward Chow Comment On Regulatory Notice 22-08
Evgeny Pogorelov Comment On Regulatory Notice 22-08
Donald Kirsch Comment On Regulatory Notice 22-08
Jeffrey Gabler Comment On Regulatory Notice 22-08
Charles Mabry Comment On Regulatory Notice 22-08
Charles Hylen Comment On Regulatory Notice 22-08
Ronald Maehl Comment On Regulatory Notice 22-08
James Walker Comment On Regulatory Notice 22-08
Ronald Michaeloff Comment On Regulatory Notice 22-08
Boxiong Ding Comment On Regulatory Notice 22-08
Darrell Chun Comment On Regulatory Notice 22-08
Andrew Garrigan Comment On Regulatory Notice 22-08
John Nugent Comment On Regulatory Notice 22-08
Bryce Kruman Comment On Regulatory Notice 22-08
John Bence Comment On Regulatory Notice 22-08
Judson Snow Comment On Regulatory Notice 22-08
Mark Nicklay Comment On Regulatory Notice 22-08
Chintan Patel Comment On Regulatory Notice 22-08
Julia Krickhahn Comment On Regulatory Notice 22-08
Trong Turner Comment On Regulatory Notice 22-08
Yeferson Gallardo Comment On Regulatory Notice 22-08
Katia May Comment On Regulatory Notice 22-08
Jay Venka Comment On Regulatory Notice 22-08
Young Cho Comment On Regulatory Notice 22-08
Jacques Adoue Comment On Regulatory Notice 22-08
Charles Roehrich Comment On Regulatory Notice 22-08
Marian Shelton Comment On Regulatory Notice 22-08
Omar Elissa Comment On Regulatory Notice 22-08
Zhana Gunderson Comment On Regulatory Notice 22-08
Christopher Barger Comment On Regulatory Notice 22-08
Ashish Anand Comment On Regulatory Notice 22-08
Raymond T Piper Comment On Regulatory Notice 22-08
Richard Loyer Comment On Regulatory Notice 22-08
Justin Dorn Comment On Regulatory Notice 22-08
Sandra Lind Comment On Regulatory Notice 22-08
Robert Merrill Comment On Regulatory Notice 22-08
Scott Milburn Comment On Regulatory Notice 22-08
Coco Cheng Comment On Regulatory Notice 22-08
Robert Weinberg Comment On Regulatory Notice 22-08
Karunkumar Biyani Comment On Regulatory Notice 22-08
Jameka Jones Comment On Regulatory Notice 22-08
Samuel Safyan Comment On Regulatory Notice 22-08
Scott Citron Comment On Regulatory Notice 22-08
Mary Van Zandt Comment On Regulatory Notice 22-08
Gek Yeo Comment On Regulatory Notice 22-08
Scott Cornelius Comment On Regulatory Notice 22-08
Denise Allegro Comment On Regulatory Notice 22-08
Tom Madine Comment On Regulatory Notice 22-08
Adem Neziri Comment On Regulatory Notice 22-08
Samuel Safahi Comment On Regulatory Notice 22-08
Jim Catland Comment On Regulatory Notice 22-08
Gary Carr Comment On Regulatory Notice 22-08
Yinka Ajetunmobi Comment On Regulatory Notice 22-08
Robert Fee Comment On Regulatory Notice 22-08
Ben Brockman Comment On Regulatory Notice 22-08
Dean Weinberger Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Tom Leo Comment On Regulatory Notice 22-08
Zak Ghannam Comment On Regulatory Notice 22-08
Derek Tinoco Comment On Regulatory Notice 22-08
Nelson Gikbein Comment On Regulatory Notice 22-08
David Wolfgang Comment On Regulatory Notice 22-08
Bill Winn Comment On Regulatory Notice 22-08
Van Van Wyk Comment On Regulatory Notice 22-08
Bernard Cohen Comment On Regulatory Notice 22-08
Barbara Thibault Comment On Regulatory Notice 22-08
Charles Gage Comment On Regulatory Notice 22-08
Sam Augusta Comment On Regulatory Notice 22-08
Benedict LeVal Comment On Regulatory Notice 22-08
Michael Hayes Comment On Regulatory Notice 22-08
Terry Bussard Comment On Regulatory Notice 22-08
Marybeth Durland Comment On Regulatory Notice 22-08
Kenneth Higgins Comment On Regulatory Notice 22-08
Arthur Grensing Comment On Regulatory Notice 22-08
Raymond Olenic Comment On Regulatory Notice 22-08
Frank Paladino Comment On Regulatory Notice 22-08
Rachel Mariotti Comment On Regulatory Notice 22-08
Steve Rumsey Comment On Regulatory Notice 22-08
Hahns Copeland Comment On Regulatory Notice 22-08
Paul Manning Comment On Regulatory Notice 22-08
Jeremy Coleman Comment On Regulatory Notice 22-08
William Terhune Comment On Regulatory Notice 22-08
Nick Basso Comment On Regulatory Notice 22-08
Reynolds Clodfelter Comment On Regulatory Notice 22-08
Talal Mased Comment On Regulatory Notice 22-08
David Harris Comment On Regulatory Notice 22-08
Cooper Bailey Comment On Regulatory Notice 22-08
Analyn Sahachaisere Comment On Regulatory Notice 22-08
Paul Kliman Comment On Regulatory Notice 22-08
Richard Cuesta Comment On Regulatory Notice 22-08
Ben Simpson Comment On Regulatory Notice 22-08
Evans Lee Comment On Regulatory Notice 22-08
Andrew Cochran Comment On Regulatory Notice 22-08
Jason Beverly Comment On Regulatory Notice 22-08
David Wilhite Comment On Regulatory Notice 22-08
Juan Benitez Comment On Regulatory Notice 22-08
Donald Petersen Comment On Regulatory Notice 22-08
David Haughney Comment On Regulatory Notice 22-08
George Aubrey Comment On Regulatory Notice 22-08
Steven Rossi Comment On Regulatory Notice 22-08
Harold Campbell Comment On Regulatory Notice 22-08
James White Comment On Regulatory Notice 22-08
Jason Gallagher Comment On Regulatory Notice 22-08
Denise Mier Comment On Regulatory Notice 22-08
Linda Shaw Comment On Regulatory Notice 22-08
Tate Dwinnell Comment On Regulatory Notice 22-08
Donna Haybarger Comment On Regulatory Notice 22-08
Harold Collins Comment On Regulatory Notice 22-08
Randall Eden Comment On Regulatory Notice 22-08
Daniel O'Sullivan Comment On Regulatory Notice 22-08
Nathan Coleman Comment On Regulatory Notice 22-08
Paramjit Chumber Comment On Regulatory Notice 22-08
Will Clark Comment On Regulatory Notice 22-08
Henry Chen Comment On Regulatory Notice 22-08
Nina Levent Comment On Regulatory Notice 22-08
Thomas Richason Comment On Regulatory Notice 22-08
Frederic Fung Comment On Regulatory Notice 22-08
Sharon Duranza Comment On Regulatory Notice 22-08
HuaHui Ou Comment On Regulatory Notice 22-08
Karen Friedhaber Comment On Regulatory Notice 22-08
Kurtis Lightheart Comment On Regulatory Notice 22-08
Stephen Vitale Comment On Regulatory Notice 22-08
Jimy Uranwala Comment On Regulatory Notice 22-08
Kevin Patterson Comment On Regulatory Notice 22-08
Derek Fuentes Comment On Regulatory Notice 22-08
Robin Ross Comment On Regulatory Notice 22-08
Samuel Brady Comment On Regulatory Notice 22-08
James Donahue Comment On Regulatory Notice 22-08
David Koziara Comment On Regulatory Notice 22-08
John OHanlan Comment On Regulatory Notice 22-08
Joseph Santa Comment On Regulatory Notice 22-08
Cole Jeff Comment On Regulatory Notice 22-08
James Stone Comment On Regulatory Notice 22-08
Christopher Polson Comment On Regulatory Notice 22-08
Andy Chan Comment On Regulatory Notice 22-08
Anton Widmer Comment On Regulatory Notice 22-08
Stuart Morgan Comment On Regulatory Notice 22-08
Valentine Correia Comment On Regulatory Notice 22-08
James LeBoeuf Comment On Regulatory Notice 22-08
Georgene Hehn Comment On Regulatory Notice 22-08
Jeffery Trudel Comment On Regulatory Notice 22-08
Clayton Carncross Comment On Regulatory Notice 22-08
li Trinh Comment On Regulatory Notice 22-08
Kirti Makati Comment On Regulatory Notice 22-08
Val Pedroza Comment On Regulatory Notice 22-08
Yanbo Zhu Comment On Regulatory Notice 22-08
Wade Pulliam Comment On Regulatory Notice 22-08
Tarun Gupta Comment On Regulatory Notice 22-08
Dan Grimes Comment On Regulatory Notice 22-08
Carol Wallach Comment On Regulatory Notice 22-08
Robert Bolden Comment On Regulatory Notice 22-08
Jeffrey Kline Comment On Regulatory Notice 22-08
Arthur Diefenbach Comment On Regulatory Notice 22-08
David Newkirk Comment On Regulatory Notice 22-08
Chris Leinbach Comment On Regulatory Notice 22-08
David Strasser Comment On Regulatory Notice 22-08
Saylor Cleaver Comment On Regulatory Notice 22-08
Kemba Armstead Comment On Regulatory Notice 22-08
KC Contracto Comment On Regulatory Notice 22-08
Bradon Van Leuven Comment On Regulatory Notice 22-08
Carlos Nunez Comment On Regulatory Notice 22-08
Brian McGrath Comment On Regulatory Notice 22-08
Anil Ladalla Comment On Regulatory Notice 22-08
Christine Brew Comment On Regulatory Notice 22-08
John Ingles Comment On Regulatory Notice 22-08
Sue Yamamoto Comment On Regulatory Notice 22-08
William Sonon Comment On Regulatory Notice 22-08
Amanda Gayle Comment On Regulatory Notice 22-08
Calvin Fields Comment On Regulatory Notice 22-08
Austen Hoogen Comment On Regulatory Notice 22-08
Kyle Dennis Comment On Regulatory Notice 22-08
Carlos Ortega Comment On Regulatory Notice 22-08
Chih-Sian Chen Comment On Regulatory Notice 22-08
Harry Huskey Comment On Regulatory Notice 22-08
Dustin Romano Comment On Regulatory Notice 22-08
Jeff Barczak Comment On Regulatory Notice 22-08
Howard Lambert Comment On Regulatory Notice 22-08
Gil Morales Comment On Regulatory Notice 22-08
Casey Krueger Comment On Regulatory Notice 22-08
Yim Barry Comment On Regulatory Notice 22-08
Jorge Pinto Comment On Regulatory Notice 22-08
Michael McCarrell Comment On Regulatory Notice 22-08
Carl Klepczynski Comment On Regulatory Notice 22-08
Ken Morledge Comment On Regulatory Notice 22-08
Bruce Clancy Comment On Regulatory Notice 22-08
Samantha Xue Comment On Regulatory Notice 22-08
Brandon Kennedy Comment On Regulatory Notice 22-08
Bobby Burns Comment On Regulatory Notice 22-08
Mohammar Al-Habash Comment On Regulatory Notice 22-08
David Kisor Comment On Regulatory Notice 22-08
Jianping Zhou Comment On Regulatory Notice 22-08
Jake Thompson Comment On Regulatory Notice 22-08
Robert Munster Comment On Regulatory Notice 22-08
Bruce Capers Comment On Regulatory Notice 22-08
Theresa Petticini Comment On Regulatory Notice 22-08
William Mathers Comment On Regulatory Notice 22-08
Zuwei Liu Comment On Regulatory Notice 22-08
Margaret Toale Comment On Regulatory Notice 22-08
Charles Maurhoff Comment On Regulatory Notice 22-08
Thomas Manzagol Comment On Regulatory Notice 22-08
Sam Song Comment On Regulatory Notice 22-08
Liza Maltz Comment On Regulatory Notice 22-08
Mark Robinson Comment On Regulatory Notice 22-08
Yuchen Chen Comment On Regulatory Notice 22-08
Nick Johnston Comment On Regulatory Notice 22-08
Chuck Earle Comment On Regulatory Notice 22-08
Kenney Tormaschy Comment On Regulatory Notice 22-08
Predrag Cvetkovski Comment On Regulatory Notice 22-08
Michael Kurtser Comment On Regulatory Notice 22-08
Anthony Obrien Comment On Regulatory Notice 22-08
Thomas Quammen Comment On Regulatory Notice 22-08
Dennis Morrison Comment On Regulatory Notice 22-08
David Fink Comment On Regulatory Notice 22-08
John Smolski Comment On Regulatory Notice 22-08
John Stout Comment On Regulatory Notice 22-08
Michael Masello Comment On Regulatory Notice 22-08
Mark Horner Comment On Regulatory Notice 22-08
Dennis Manuel Comment On Regulatory Notice 22-08
Tadeusz Andruczyk Comment On Regulatory Notice 22-08
Sean Scanlan Comment On Regulatory Notice 22-08
Frederick Chan Comment On Regulatory Notice 22-08
Taposh Chatterjee Comment On Regulatory Notice 22-08
David Voelker Comment On Regulatory Notice 22-08
Joseph Burnett Comment On Regulatory Notice 22-08
Joyce Vierra Comment On Regulatory Notice 22-08
Matthew Alden Comment On Regulatory Notice 22-08
Phang Wibowo Comment On Regulatory Notice 22-08
Andrew Ozor Comment On Regulatory Notice 22-08
William Reeves Comment On Regulatory Notice 22-08
Hongan Chen Comment On Regulatory Notice 22-08
Gregg Stevens Comment On Regulatory Notice 22-08
Gang Yang Comment On Regulatory Notice 22-08
Jason Jurgens Comment On Regulatory Notice 22-08
Dale Look Comment On Regulatory Notice 22-08
Timothy Baker Comment On Regulatory Notice 22-08
Ondine McBurney Comment On Regulatory Notice 22-08
Juan Rivas Comment On Regulatory Notice 22-08
Adrian Hernandez Comment On Regulatory Notice 22-08
Thomas Odmark Comment On Regulatory Notice 22-08
Sam Hsiao Comment On Regulatory Notice 22-08
Carl Coe Comment On Regulatory Notice 22-08
Ken Wang Comment On Regulatory Notice 22-08
Gregory Souran Comment On Regulatory Notice 22-08
Blaine Weber Comment On Regulatory Notice 22-08
Bob Rummell Comment On Regulatory Notice 22-08
Wen-Chen Su Comment On Regulatory Notice 22-08
Steven Sterner Comment On Regulatory Notice 22-08
Michael Henriques Comment On Regulatory Notice 22-08
James Conlin Comment On Regulatory Notice 22-08
George Blattner Comment On Regulatory Notice 22-08
Kim Hanechak Comment On Regulatory Notice 22-08
Christine Parma Comment On Regulatory Notice 22-08
Tiejun Zhang Comment On Regulatory Notice 22-08
Gerard Williams Comment On Regulatory Notice 22-08
Brett Baker Comment On Regulatory Notice 22-08
Jayasankar Gopalakrishnan Comment On Regulatory Notice 22-08
Elaine Shaw Comment On Regulatory Notice 22-08
Adam Thomas Comment On Regulatory Notice 22-08
Dan Allen Comment On Regulatory Notice 22-08
Sandra Whittaker Comment On Regulatory Notice 22-08
Caroline Ippolito Comment On Regulatory Notice 22-08
Brian Tobin Comment On Regulatory Notice 22-08
Samuel Ludwig Comment On Regulatory Notice 22-08
William Kenyon Comment On Regulatory Notice 22-08
Rahul Soparawala Comment On Regulatory Notice 22-08
Mark Knowles Comment On Regulatory Notice 22-08
Wahid Sediqe Comment On Regulatory Notice 22-08
Kittredge James Comment On Regulatory Notice 22-08
Reginald Campbell Comment On Regulatory Notice 22-08
Doug Austin Comment On Regulatory Notice 22-08
Chris Hayes Comment On Regulatory Notice 22-08
Karel Bognar Comment On Regulatory Notice 22-08
Scott Hutchins Comment On Regulatory Notice 22-08
Rick Staggs Comment On Regulatory Notice 22-08
David Nichols Comment On Regulatory Notice 22-08
Steve Schwartz Comment On Regulatory Notice 22-08
Charles Kurtz Comment On Regulatory Notice 22-08
Olaosebikan Omotayo Comment On Regulatory Notice 22-08
Liam Shanahan Comment On Regulatory Notice 22-08
Alexander Ramirez Comment On Regulatory Notice 22-08
Pratik Patel Comment On Regulatory Notice 22-08
Stewart Mock Comment On Regulatory Notice 22-08
Sean Fenlon Comment On Regulatory Notice 22-08
Daniel Campos Comment On Regulatory Notice 22-08
Ludmila Hironymous Comment On Regulatory Notice 22-08
Harish Koolwal Comment On Regulatory Notice 22-08
Medardo Hernandez Comment On Regulatory Notice 22-08
Mark Walch Comment On Regulatory Notice 22-08
Gary Upperman Comment On Regulatory Notice 22-08
Vicram Gupta Comment On Regulatory Notice 22-08
Lewix Liu Comment On Regulatory Notice 22-08
Darrel Wallace Comment On Regulatory Notice 22-08
Scott Usedom Comment On Regulatory Notice 22-08
Peter Arendt Comment On Regulatory Notice 22-08
David Ferguosn Comment On Regulatory Notice 22-08
Jason Maine Comment On Regulatory Notice 22-08
Yang Song Comment On Regulatory Notice 22-08
Samuel Donovan Comment On Regulatory Notice 22-08
Phillip Ranelli Comment On Regulatory Notice 22-08
Milan Todorovich Comment On Regulatory Notice 22-08
Chris Sturgis Comment On Regulatory Notice 22-08
Dimitry Tihomirov Comment On Regulatory Notice 22-08
Tony Willingham Comment On Regulatory Notice 22-08
Wendy Hebestreit-Johnson Comment On Regulatory Notice 22-08
Jonathan Slavin Comment On Regulatory Notice 22-08
David Walker Comment On Regulatory Notice 22-08
Jeff Grambort Comment On Regulatory Notice 22-08
John Cayton Comment On Regulatory Notice 22-08
Michael Elkins Comment On Regulatory Notice 22-08
Anonymous Comment On Regulatory Notice 22-08
Ravi Sood Comment On Regulatory Notice 22-08
Steve Taymor Comment On Regulatory Notice 22-08
Eugene Mirkin Comment On Regulatory Notice 22-08
Jon McMahon Comment On Regulatory Notice 22-08
Snehal Desai Comment On Regulatory Notice 22-08
Alexei Remizov Comment On Regulatory Notice 22-08
Scott Denison Comment On Regulatory Notice 22-08
Joel Woods Comment On Regulatory Notice 22-08
Monte Carpentier Comment On Regulatory Notice 22-08
Joseph Ha Comment On Regulatory Notice 22-08
Richard Steinbrenner Comment On Regulatory Notice 22-08
Mei Xue Comment On Regulatory Notice 22-08
John Abreu Comment On Regulatory Notice 22-08
Ross Wesner Comment On Regulatory Notice 22-08
Denise Domingo Comment On Regulatory Notice 22-08
Ronnie Jourdan Comment On Regulatory Notice 22-08
Dr. Patel Comment On Regulatory Notice 22-08
Charles Charles Comment On Regulatory Notice 22-08
Gabriel Jones Comment On Regulatory Notice 22-08
John Potye Comment On Regulatory Notice 22-08
Shane O'Brien Comment On Regulatory Notice 22-08
Rasa Gierstikas Comment On Regulatory Notice 22-08
Shahrzad Gerdvisheh Comment On Regulatory Notice 22-08
Juan Urena Comment On Regulatory Notice 22-08
Rolin Blake Comment On Regulatory Notice 22-08
James VanBolhuis Comment On Regulatory Notice 22-08
Peter DeMichele Comment On Regulatory Notice 22-08
Theodore Pasquale Comment On Regulatory Notice 22-08
Jason Beiriger Comment On Regulatory Notice 22-08
Neil Raisanen Comment On Regulatory Notice 22-08
Daniel Gabbard Comment On Regulatory Notice 22-08
James McClure Comment On Regulatory Notice 22-08
Paul Witmer Comment On Regulatory Notice 22-08
Theodore Linde Comment On Regulatory Notice 22-08
Ahmed Tayfour Comment On Regulatory Notice 22-08
Donald Holcomb Comment On Regulatory Notice 22-08
Sean Hyman Comment On Regulatory Notice 22-08
Thomas Gutman Comment On Regulatory Notice 22-08
Elana Maya Comment On Regulatory Notice 22-08
James Swindler Comment On Regulatory Notice 22-08
Herbert Polley Comment On Regulatory Notice 22-08
Harry Vernon Comment On Regulatory Notice 22-08
Lap Chan Comment On Regulatory Notice 22-08
Kevin Martin Comment On Regulatory Notice 22-08
Kusai Contractor Comment On Regulatory Notice 22-08
Kenneth Malloy Comment On Regulatory Notice 22-08
Raju Datla Comment On Regulatory Notice 22-08
Rhonda Elhosseiny Comment On Regulatory Notice 22-08
John Gumina Comment On Regulatory Notice 22-08
Jonathan Owen Comment On Regulatory Notice 22-08
Stephen Jones Comment On Regulatory Notice 22-08
Leonard Grego Comment On Regulatory Notice 22-08
David Robertson Comment On Regulatory Notice 22-08
Steve Williams Comment On Regulatory Notice 22-08
Christopher Norce Comment On Regulatory Notice 22-08
Fuquan Wang Comment On Regulatory Notice 22-08
Howard Gordon Comment On Regulatory Notice 22-08
Don Merrell Comment On Regulatory Notice 22-08
Robert Decker Comment On Regulatory Notice 22-08
Brian Reeves Comment On Regulatory Notice 22-08
Tony Swartz Comment On Regulatory Notice 22-08
Ryan Schaap Comment On Regulatory Notice 22-08
Lesha Garrett Comment On Regulatory Notice 22-08
Frank Hawker Comment On Regulatory Notice 22-08
Scott Deidun Comment On Regulatory Notice 22-08
Howard Fiedler Comment On Regulatory Notice 22-08
Viren Gilani Comment On Regulatory Notice 22-08
James Smith Comment On Regulatory Notice 22-08
Muhammad Abdullah Comment On Regulatory Notice 22-08
Theodore Marley Comment On Regulatory Notice 22-08
Adam Bratter Comment On Regulatory Notice 22-08
Kirk Martin Comment On Regulatory Notice 22-08
Scott Soper Comment On Regulatory Notice 22-08
Jonathan Bulnes Comment On Regulatory Notice 22-08
Edward Skopal Comment On Regulatory Notice 22-08
Bryan Tunney Comment On Regulatory Notice 22-08
Miguel Sepulveda Comment On Regulatory Notice 22-08
P Dev Comment On Regulatory Notice 22-08
Carol Sampsel Comment On Regulatory Notice 22-08
Xiaobing Wu Comment On Regulatory Notice 22-08
Julie Zhu Comment On Regulatory Notice 22-08
Michael Timmons Comment On Regulatory Notice 22-08
David Raymie Comment On Regulatory Notice 22-08
Herbert Mohaupt Comment On Regulatory Notice 22-08
Michael Adams Comment On Regulatory Notice 22-08
Monte Carpentier Comment On Regulatory Notice 22-08
Holland Brown Comment On Regulatory Notice 22-08
Eric Jostock Comment On Regulatory Notice 22-08
Gary Omlid Comment On Regulatory Notice 22-08
John Conlisk Comment On Regulatory Notice 22-08
Stephen Hanley Comment On Regulatory Notice 22-08
Brett Beerer Comment On Regulatory Notice 22-08
Emily Hummel Comment On Regulatory Notice 22-08
Dena Motevalian Comment On Regulatory Notice 22-08
Richard May Comment On Regulatory Notice 22-08
Kenneth Loebel Comment On Regulatory Notice 22-08
Angelo Dibartolomeo Comment On Regulatory Notice 22-08
Amy Bolden Comment On Regulatory Notice 22-08
Shan Dagli Comment On Regulatory Notice 22-08
Ashlyn Croft Comment On Regulatory Notice 22-08
Olaosebikan Omotayo Comment On Regulatory Notice 22-08
Chris Lengerich Comment On Regulatory Notice 22-08
Jonathan Sykes Comment On Regulatory Notice 22-08
Forest Hill Comment On Regulatory Notice 22-08
James Runde Comment On Regulatory Notice 22-08
Carlos Jaquez Comment On Regulatory Notice 22-08
Matthew Gibbons Comment On Regulatory Notice 22-08
Michael Gonzalez Comment On Regulatory Notice 22-08
Wei Cui Comment On Regulatory Notice 22-08
Cristina C Comment On Regulatory Notice 22-08
Keith Hirshburg Comment On Regulatory Notice 22-08
Leroy Allen Comment On Regulatory Notice 22-08
Scott Usedom Comment On Regulatory Notice 22-08
Brian Kiger Comment On Regulatory Notice 22-08
Walter Kotlarz Comment On Regulatory Notice 22-08
Sepideh Khazai Comment On Regulatory Notice 22-08
Michael Elmore Comment On Regulatory Notice 22-08
Marion Woodbury Comment On Regulatory Notice 22-08
Robert Popso Comment On Regulatory Notice 22-08
Matthew Sarnocinski Comment On Regulatory Notice 22-08
Elvira Zinnatova Comment On Regulatory Notice 22-08
Todd Hickman Comment On Regulatory Notice 22-08
Alexia Lou Comment On Regulatory Notice 22-08
Jayesh Parmar Comment On Regulatory Notice 22-08
Larry Stevenson Comment On Regulatory Notice 22-08
Greg McNair Comment On Regulatory Notice 22-08
Tarek Torgoman Comment On Regulatory Notice 22-08
Terry Quan Comment On Regulatory Notice 22-08
Jose Rodriguez Comment On Regulatory Notice 22-08
Aniello Bianco Comment On Regulatory Notice 22-08
Phillips Lohr Comment On Regulatory Notice 22-08
Ross Michler Comment On Regulatory Notice 22-08
Douglas Hamilton Comment On Regulatory Notice 22-08
Mark Garrett Comment On Regulatory Notice 22-08
Cindy Gu Comment On Regulatory Notice 22-08
Lee Lybarger Comment On Regulatory Notice 22-08
Steven Davis Comment On Regulatory Notice 22-08
Richard Ell Comment On Regulatory Notice 22-08
William Miller Comment On Regulatory Notice 22-08
Luke Irby Comment On Regulatory Notice 22-08
Minseok Kwon Comment On Regulatory Notice 22-08
William Harley Comment On Regulatory Notice 22-08
Andre Cyr Comment On Regulatory Notice 22-08
Martin Izdimirski Comment On Regulatory Notice 22-08
Palak Mathur Comment On Regulatory Notice 22-08
Bob Bones Comment On Regulatory Notice 22-08
Curtis Cooper Comment On Regulatory Notice 22-08
Curtis Davis Comment On Regulatory Notice 22-08
Vipul Chopra Comment On Regulatory Notice 22-08
Jessica Higgins Comment On Regulatory Notice 22-08
Ed Parr Comment On Regulatory Notice 22-08
Greg Watson Comment On Regulatory Notice 22-08
Evangelos Eleftheriou Comment On Regulatory Notice 22-08
Oscar Jennings Comment On Regulatory Notice 22-08
Randall Vodnik Comment On Regulatory Notice 22-08
Dan Doxsee Comment On Regulatory Notice 22-08
Yvonka Foster Comment On Regulatory Notice 22-08
Marina Saettone Comment On Regulatory Notice 22-08
Iain Davies Comment On Regulatory Notice 22-08
Rava Ladoo Comment On Regulatory Notice 22-08
Vinh Lam Comment On Regulatory Notice 22-08
Steven Brooks Comment On Regulatory Notice 22-08
Hany Malek Comment On Regulatory Notice 22-08
Warren Funk Comment On Regulatory Notice 22-08
Victor Sedaka Comment On Regulatory Notice 22-08
James Brunson Comment On Regulatory Notice 22-08
Hal Vogel Comment On Regulatory Notice 22-08
Joe Dambrosio Comment On Regulatory Notice 22-08
Steven Moranz Comment On Regulatory Notice 22-08
Jenna Wade Comment On Regulatory Notice 22-08
Jordan McDonald Comment On Regulatory Notice 22-08
Thomas Mazur Comment On Regulatory Notice 22-08
Kyle Souza Comment On Regulatory Notice 22-08
Chad Strean Comment On Regulatory Notice 22-08
Owen Freiburger Comment On Regulatory Notice 22-08
Shaun Melarvie Comment On Regulatory Notice 22-08
Nadine Khoury Comment On Regulatory Notice 22-08
Matthew Loveridge Comment On Regulatory Notice 22-08
Niranjana Makki Comment On Regulatory Notice 22-08
Franklin Parada Comment On Regulatory Notice 22-08
Yevgeny Elyash Comment On Regulatory Notice 22-08
Kei Lee Comment On Regulatory Notice 22-08
Robert Popso Comment On Regulatory Notice 22-08
Tom Davis Comment On Regulatory Notice 22-08
Mark Mahoney Comment On Regulatory Notice 22-08
Todd Hansen Comment On Regulatory Notice 22-08
Bailey Douglass Comment On Regulatory Notice 22-08
Richard Filippetti Comment On Regulatory Notice 22-08
Richard Stoddart Comment On Regulatory Notice 22-08
Rohan Venkatesh Comment On Regulatory Notice 22-08
Jason Farmer Comment On Regulatory Notice 22-08
Danelle Brown Comment On Regulatory Notice 22-08
Marian Aubry Comment On Regulatory Notice 22-08
Thomas Buchanan Comment On Regulatory Notice 22-08
Gordon Edwards Comment On Regulatory Notice 22-08
Paul Hauf Comment On Regulatory Notice 22-08
Reto Furler Comment On Regulatory Notice 22-08
Stephen Kiely Comment On Regulatory Notice 22-08
Aaron Mullis Comment On Regulatory Notice 22-08
Antonio Maldonado Comment On Regulatory Notice 22-08
Barbara Candiotti Comment On Regulatory Notice 22-08
Tim Brand Comment On Regulatory Notice 22-08
Greg Watson Comment On Regulatory Notice 22-08
R. Robinson Comment On Regulatory Notice 22-08
Geoffrey Trafton Comment On Regulatory Notice 22-08
Zhang Ying Comment On Regulatory Notice 22-08
Christopher Dehaan Comment On Regulatory Notice 22-08
Ernest Ceccato Comment On Regulatory Notice 22-08
Elliot Chalme Comment On Regulatory Notice 22-08
Amy Vaida Comment On Regulatory Notice 22-08
Mark David Comment On Regulatory Notice 22-08
Herbert Strassberg Comment On Regulatory Notice 22-08
Supraja Muppala Comment On Regulatory Notice 22-08
Zhou Fang Comment On Regulatory Notice 22-08
Ryan Hall Comment On Regulatory Notice 22-08
Vida Semsarzadeh Comment On Regulatory Notice 22-08
Lillian Shieh Comment On Regulatory Notice 22-08
Michael Basso Comment On Regulatory Notice 22-08
Raymond Paquette Comment On Regulatory Notice 22-08
Danielle King Comment On Regulatory Notice 22-08
Phil Baumann Comment On Regulatory Notice 22-08
Eli Schwartz Comment On Regulatory Notice 22-08
Michael Rijo Comment On Regulatory Notice 22-08
Ho Kim Comment On Regulatory Notice 22-08
Jaipaul Sethi Comment On Regulatory Notice 22-08
Sagan de Castro Comment On Regulatory Notice 22-08
Paul Markey Comment On Regulatory Notice 22-08
John Armour Comment On Regulatory Notice 22-08
Ashruf El-Dinary Comment On Regulatory Notice 22-08
Jose Gallardo Comment On Regulatory Notice 22-08
Thomas Price Comment On Regulatory Notice 22-08
John Barrett Comment On Regulatory Notice 22-08
Jeremiah Haremza Comment On Regulatory Notice 22-08
Thomas Powers Comment On Regulatory Notice 22-08
Peter Ma Comment On Regulatory Notice 22-08
Michael Kirchner Comment On Regulatory Notice 22-08
James Cai Comment On Regulatory Notice 22-08
William Dixon Comment On Regulatory Notice 22-08
Andrew Thio Comment On Regulatory Notice 22-08
Francesco Cionti Comment On Regulatory Notice 22-08
Todd Didier Comment On Regulatory Notice 22-08
Jesse Weston Comment On Regulatory Notice 22-08
Eric Koetters Comment On Regulatory Notice 22-08
Marcus Bowman Comment On Regulatory Notice 22-08
Isaac Kremsky Comment On Regulatory Notice 22-08
Benjamin Hernandez Comment On Regulatory Notice 22-08
Sandeep Sharma Comment On Regulatory Notice 22-08
Cristiano Soares Comment On Regulatory Notice 22-08
Ravi Dear Comment On Regulatory Notice 22-08
Russell Snyder Comment On Regulatory Notice 22-08
Pete Liao Comment On Regulatory Notice 22-08
Ryan Kane Comment On Regulatory Notice 22-08
Mert Dinc Comment On Regulatory Notice 22-08
James Muskal Comment On Regulatory Notice 22-08
Daniel Schiff Comment On Regulatory Notice 22-08
Patrick Acton Comment On Regulatory Notice 22-08
Dennis Williams Comment On Regulatory Notice 22-08
Don Cox Comment On Regulatory Notice 22-08
Marcel CFA Comment On Regulatory Notice 22-08
Elena Bagnato Comment On Regulatory Notice 22-08
Nicolas Wyse Comment On Regulatory Notice 22-08
Gina Marie Comment On Regulatory Notice 22-08
Tim Haltmeyer Comment On Regulatory Notice 22-08
Richard Scheeringa Comment On Regulatory Notice 22-08
Renyu Li Comment On Regulatory Notice 22-08
Michael Alpern Comment On Regulatory Notice 22-08
Christian Gangitano Comment On Regulatory Notice 22-08
Robert Braun Comment On Regulatory Notice 22-08
Bradley Moffatt Comment On Regulatory Notice 22-08
Jayasankar Gopalakrishnan Comment On Regulatory Notice 22-08
Leslie Durrant Comment On Regulatory Notice 22-08
Robert Flesch Comment On Regulatory Notice 22-08
Barrett Gold Comment On Regulatory Notice 22-08
Kenneth Simmons Comment On Regulatory Notice 22-08
Taggart Ridings Comment On Regulatory Notice 22-08
Jared Garabedian Comment On Regulatory Notice 22-08
Michael Lindell Comment On Regulatory Notice 22-08
David Wallis Comment On Regulatory Notice 22-08
Charlie Sault Comment On Regulatory Notice 22-08
John Lehett Comment On Regulatory Notice 22-08
Lawrence Dickinson Comment On Regulatory Notice 22-08
Hyland Oliver Comment On Regulatory Notice 22-08
Jeffrey Abbott Comment On Regulatory Notice 22-08
Charles Engelberg Comment On Regulatory Notice 22-08
Brenda Anthony Comment On Regulatory Notice 22-08
Cong Pou Comment On Regulatory Notice 22-08
Sidney Chen Comment On Regulatory Notice 22-08
Sriram Mircha Comment On Regulatory Notice 22-08
Thomas Boey Comment On Regulatory Notice 22-08
James Docherty Comment On Regulatory Notice 22-08
Joseph Lucero Comment On Regulatory Notice 22-08
Carol Sampsel Comment On Regulatory Notice 22-08
Roman Nurilov Comment On Regulatory Notice 22-08
Glenn Tortoso Comment On Regulatory Notice 22-08
Alexandra Chiafullo Comment On Regulatory Notice 22-08
Robert Parker Comment On Regulatory Notice 22-08
Curtis DeLaughter Comment On Regulatory Notice 22-08
Gaby Ata Comment On Regulatory Notice 22-08
Haitao Tan Comment On Regulatory Notice 22-08
Christopher Marquart Comment On Regulatory Notice 22-08
David Lademan Comment On Regulatory Notice 22-08
Charles Stasoiski Comment On Regulatory Notice 22-08
Claire Lapaan Comment On Regulatory Notice 22-08
Huey Guo Comment On Regulatory Notice 22-08
Shannon Alves Comment On Regulatory Notice 22-08
Amine Fehmi Comment On Regulatory Notice 22-08
Gregory Schmidt Comment On Regulatory Notice 22-08
Jatin Bidani Comment On Regulatory Notice 22-08
Jacob Mitchell Comment On Regulatory Notice 22-08
Joseph Simon Comment On Regulatory Notice 22-08
Michael Goldman Comment On Regulatory Notice 22-08
Robert Naujokas Comment On Regulatory Notice 22-08
Ricky Silk Comment On Regulatory Notice 22-08
Sergio Estrada Comment On Regulatory Notice 22-08
Howard Huang Comment On Regulatory Notice 22-08
Ryan Roylance Comment On Regulatory Notice 22-08
Roy Leslie Comment On Regulatory Notice 22-08
Colin Huff Comment On Regulatory Notice 22-08
Todd Williamson Comment On Regulatory Notice 22-08
Yi Sun Comment On Regulatory Notice 22-08
Piero Marinucci Comment On Regulatory Notice 22-08
Steven Rothacker Comment On Regulatory Notice 22-08
Brian Hunley Comment On Regulatory Notice 22-08
Walter Chu Comment On Regulatory Notice 22-08
Rob Hollman Comment On Regulatory Notice 22-08
Chuck Adams Comment On Regulatory Notice 22-08
Joseph Mess Comment On Regulatory Notice 22-08
Melinda Abood Comment On Regulatory Notice 22-08
Jerry Carter Comment On Regulatory Notice 22-08
Andrew Hines Comment On Regulatory Notice 22-08
Vijay Nagappa Comment On Regulatory Notice 22-08
Carlos Giron Comment On Regulatory Notice 22-08
Richard Gordon Comment On Regulatory Notice 22-08
Erik Hansen Comment On Regulatory Notice 22-08
David Gross Comment On Regulatory Notice 22-08
Paul Ingbretsen Comment On Regulatory Notice 22-08
M Gropman Comment On Regulatory Notice 22-08
Ronald Woloshan Comment On Regulatory Notice 22-08
Hemantkumar Sheth Comment On Regulatory Notice 22-08
Jeff Jeans Comment On Regulatory Notice 22-08
Dennis O. Comment On Regulatory Notice 22-08
Jenifer Taylor Comment On Regulatory Notice 22-08
William Lyons Comment On Regulatory Notice 22-08
Jen Lin Comment On Regulatory Notice 22-08
Lillian Shieh Comment On Regulatory Notice 22-08
Jon Wolfenbarger Comment On Regulatory Notice 22-08
Stephen Myers Comment On Regulatory Notice 22-08
Thomas Cegelski Comment On Regulatory Notice 22-08
Frank Benson Comment On Regulatory Notice 22-08
Zhiping Wen Comment On Regulatory Notice 22-08
Keith Menter Comment On Regulatory Notice 22-08
Ronald Chippi Comment On Regulatory Notice 22-08
Scott Kuelker Comment On Regulatory Notice 22-08
Cameron Miller Comment On Regulatory Notice 22-08
Harshad Dave Comment On Regulatory Notice 22-08
Mahendra Devarapalli Comment On Regulatory Notice 22-08
John Sabo Comment On Regulatory Notice 22-08
Andrew White Comment On Regulatory Notice 22-08
Ajay Sharma Comment On Regulatory Notice 22-08
David Byers Comment On Regulatory Notice 22-08
Cesar Ramos Comment On Regulatory Notice 22-08
Devin Weiss Comment On Regulatory Notice 22-08
Al Gale Comment On Regulatory Notice 22-08
Jonathan Leman Comment On Regulatory Notice 22-08
Shamima Contractor Comment On Regulatory Notice 22-08
Jeremiah Minifield Comment On Regulatory Notice 22-08
Robert Kline Comment On Regulatory Notice 22-08
Keith Vierbicky Comment On Regulatory Notice 22-08
David Canale Comment On Regulatory Notice 22-08
Pranav Shah Comment On Regulatory Notice 22-08
Paul Geisler Comment On Regulatory Notice 22-08
Mareshkumar Shah Comment On Regulatory Notice 22-08
Deborah Maguire Comment On Regulatory Notice 22-08
Edmund Kirker Comment On Regulatory Notice 22-08
Sun Lee Comment On Regulatory Notice 22-08
Donald Teiser Comment On Regulatory Notice 22-08
Ian Failing Comment On Regulatory Notice 22-08
Michael Phillips Comment On Regulatory Notice 22-08
John Genord Comment On Regulatory Notice 22-08
Matthew Avery Comment On Regulatory Notice 22-08
Timothy Belloto Comment On Regulatory Notice 22-08
Wayne Chudleigh Comment On Regulatory Notice 22-08
John Hanson Comment On Regulatory Notice 22-08
Thomas Day Comment On Regulatory Notice 22-08
Joseph Francis Comment On Regulatory Notice 22-08
Witt Wang Comment On Regulatory Notice 22-08
Patrick Donkers Comment On Regulatory Notice 22-08
Diane Zahm Comment On Regulatory Notice 22-08
Ven Kottapalli Comment On Regulatory Notice 22-08
Steven Morman Comment On Regulatory Notice 22-08
Charles Thomas Comment On Regulatory Notice 22-08
Nick Perlick Comment On Regulatory Notice 22-08
Dae Shin Comment On Regulatory Notice 22-08
Steve Craige Comment On Regulatory Notice 22-08
Mark Henning Comment On Regulatory Notice 22-08
James Houx Comment On Regulatory Notice 22-08
Lew Christman Comment On Regulatory Notice 22-08
Jerry Johnson Comment On Regulatory Notice 22-08
Lawrence Lok Comment On Regulatory Notice 22-08
William Demers Comment On Regulatory Notice 22-08
Patrick Eastman Comment On Regulatory Notice 22-08
Rixey Jenkins Comment On Regulatory Notice 22-08
Alex Nathan Comment On Regulatory Notice 22-08
Paul Wentz Comment On Regulatory Notice 22-08
Richard Reed Comment On Regulatory Notice 22-08
Sam Levine Comment On Regulatory Notice 22-08
Pengfei Xu Comment On Regulatory Notice 22-08
Bret Miller Comment On Regulatory Notice 22-08
Harry Lewis Comment On Regulatory Notice 22-08
Jonathan Kim Comment On Regulatory Notice 22-08
Brian Sather Comment On Regulatory Notice 22-08
Schuyler Bishop Comment On Regulatory Notice 22-08
John Poropat Comment On Regulatory Notice 22-08
Shawn Murphy Comment On Regulatory Notice 22-08
William Chalmers Comment On Regulatory Notice 22-08
James Ward Comment On Regulatory Notice 22-08
Eric Francis Comment On Regulatory Notice 22-08
Herb Holroyd Comment On Regulatory Notice 22-08
Rich Freeman Comment On Regulatory Notice 22-08
Mark Hollingsworth Comment On Regulatory Notice 22-08
Greg Ische Comment On Regulatory Notice 22-08
Louis Henken Comment On Regulatory Notice 22-08
James Caudill Comment On Regulatory Notice 22-08
Matt Oestreich Comment On Regulatory Notice 22-08
Tyler Grew Comment On Regulatory Notice 22-08
Henry Chen Comment On Regulatory Notice 22-08
Hugh Coffey Comment On Regulatory Notice 22-08
Bruce Painton Comment On Regulatory Notice 22-08
James Bonlie Comment On Regulatory Notice 22-08
Keith Steller Comment On Regulatory Notice 22-08
Jeff Bailey Comment On Regulatory Notice 22-08
Heather Von Hortenau Comment On Regulatory Notice 22-08
Jesus Mesa Comment On Regulatory Notice 22-08
Ed Washak Comment On Regulatory Notice 22-08
John Macchia Comment On Regulatory Notice 22-08
Fred Johnston Comment On Regulatory Notice 22-08
Amine Fehmi Comment On Regulatory Notice 22-08
Charles Richter Comment On Regulatory Notice 22-08
Monica Chu Comment On Regulatory Notice 22-08
Eric Wicinski Comment On Regulatory Notice 22-08
Kelly Fuerte Comment On Regulatory Notice 22-08
Andrew Wilbik Comment On Regulatory Notice 22-08
Sam Bertolino Comment On Regulatory Notice 22-08
Kevin Yang Comment On Regulatory Notice 22-08
Andrew Panaccione Comment On Regulatory Notice 22-08
Carl Kicklighter Comment On Regulatory Notice 22-08
Nugzar Nebieridze Comment On Regulatory Notice 22-08
Peter Wu Comment On Regulatory Notice 22-08
Philip Karau Comment On Regulatory Notice 22-08
K Clougherty Comment On Regulatory Notice 22-08
Carl Unterweiser Comment On Regulatory Notice 22-08
Kim-Anh Tran Comment On Regulatory Notice 22-08
Mark Walsh Comment On Regulatory Notice 22-08
Mohammad Asad Comment On Regulatory Notice 22-08
Michael Friedel Comment On Regulatory Notice 22-08
John Moran Comment On Regulatory Notice 22-08
Todd Van Paris Comment On Regulatory Notice 22-08
Thomas Sowar Comment On Regulatory Notice 22-08
James Unwin Comment On Regulatory Notice 22-08
Lonna Carter Comment On Regulatory Notice 22-08
Charles Maron Comment On Regulatory Notice 22-08
Arun Srinivasan Comment On Regulatory Notice 22-08
Tim Brand Comment On Regulatory Notice 22-08
Ailsa Carpenter Comment On Regulatory Notice 22-08
Dorothy DeMay Comment On Regulatory Notice 22-08
Allen Oldenburg Comment On Regulatory Notice 22-08
Erik Lofstrand Comment On Regulatory Notice 22-08
Omar Lopez Comment On Regulatory Notice 22-08
William Giangrande Comment On Regulatory Notice 22-08
Dorian Parola Comment On Regulatory Notice 22-08
Geoffrey Moore Comment On Regulatory Notice 22-08
Clay Broussard Comment On Regulatory Notice 22-08
Kristofer Kaba Comment On Regulatory Notice 22-08
Rao Joginpally Comment On Regulatory Notice 22-08
Sven Serneels Comment On Regulatory Notice 22-08
Bonnie Kincaid Comment On Regulatory Notice 22-08
Justin Todd Comment On Regulatory Notice 22-08
Ellen Sandles Comment On Regulatory Notice 22-08
Lillian Shieh Comment On Regulatory Notice 22-08
Edgardo Vargas Comment On Regulatory Notice 22-08
Kazuyuki Nakayama Comment On Regulatory Notice 22-08
Dan Daniel Comment On Regulatory Notice 22-08
Douglas Hough Comment On Regulatory Notice 22-08
Michael Schafer Comment On Regulatory Notice 22-08
Justin Tabb Comment On Regulatory Notice 22-08
Victor Draper Comment On Regulatory Notice 22-08
Thomas Kinzie Comment On Regulatory Notice 22-08
Cindy Gu Comment On Regulatory Notice 22-08
Zeviel Persellin Comment On Regulatory Notice 22-08
Victor Harrell Comment On Regulatory Notice 22-08
Lonnie Kirschenmann Comment On Regulatory Notice 22-08
Eric Goo Comment On Regulatory Notice 22-08
William Sandidge Comment On Regulatory Notice 22-08
Rodger Mcccarty Comment On Regulatory Notice 22-08
Donald Creech Comment On Regulatory Notice 22-08
Larry Llewellyn Comment On Regulatory Notice 22-08
William Hinton Comment On Regulatory Notice 22-08
William Tucker Comment On Regulatory Notice 22-08
Suzanne Dobbins Comment On Regulatory Notice 22-08
John Nusslein Comment On Regulatory Notice 22-08
Thomas Olache Comment On Regulatory Notice 22-08
Ammon Hitchcock Comment On Regulatory Notice 22-08
Robert Bayer Comment On Regulatory Notice 22-08
Ana Sanchez Comment On Regulatory Notice 22-08
Scott Edwards Comment On Regulatory Notice 22-08
Nithyananda Narayana Comment On Regulatory Notice 22-08
Sibi Joseph Comment On Regulatory Notice 22-08
Joseph Albanese Comment On Regulatory Notice 22-08
Wade Billiot Comment On Regulatory Notice 22-08
Eric Toth Comment On Regulatory Notice 22-08
Leo Lewitan Comment On Regulatory Notice 22-08
Stephen Sargeant Comment On Regulatory Notice 22-08
Corey Maness Comment On Regulatory Notice 22-08
Anthony Delucia Comment On Regulatory Notice 22-08
Carlos Curbelo Comment On Regulatory Notice 22-08
David Krumholz Comment On Regulatory Notice 22-08
Edgar Smith Comment On Regulatory Notice 22-08
Nick de Paula Comment On Regulatory Notice 22-08
Gerald Staffin Comment On Regulatory Notice 22-08
Kal Gettle Comment On Regulatory Notice 22-08
Tom Panucci Comment On Regulatory Notice 22-08
Keturah Miller Comment On Regulatory Notice 22-08
Ray Luo Comment On Regulatory Notice 22-08
Mark Barnes Comment On Regulatory Notice 22-08
Timothy Murray Comment On Regulatory Notice 22-08
T H Comment On Regulatory Notice 22-08
Randall Stone Comment On Regulatory Notice 22-08
David Ruiz Comment On Regulatory Notice 22-08
Phillip Marinovich Comment On Regulatory Notice 22-08
Conrad Kockerbeck Comment On Regulatory Notice 22-08
Wayne Harris Comment On Regulatory Notice 22-08
Christine Forrest Comment On Regulatory Notice 22-08
Nick Deleo Comment On Regulatory Notice 22-08
Clay Broussard Comment On Regulatory Notice 22-08
Anthony Pittarelli Comment On Regulatory Notice 22-08
Adam Walls Comment On Regulatory Notice 22-08
Franklin Ramirez Comment On Regulatory Notice 22-08
Carter Randolph Comment On Regulatory Notice 22-08
Jason Ware Comment On Regulatory Notice 22-08
Ricky Krisle Comment On Regulatory Notice 22-08
Jay Maltais Comment On Regulatory Notice 22-08
Stewart McIver Comment On Regulatory Notice 22-08
Douglas Davidson Comment On Regulatory Notice 22-08
Max Dirnfeld Comment On Regulatory Notice 22-08
James Stone Comment On Regulatory Notice 22-08
Basil Pelensky Comment On Regulatory Notice 22-08
Tyler Morgan Comment On Regulatory Notice 22-08
Stephen Chen Comment On Regulatory Notice 22-08
Trevor Peterson Comment On Regulatory Notice 22-08
Muralidhar Annapureddy Comment On Regulatory Notice 22-08
Azher Mustafa Comment On Regulatory Notice 22-08
Mark Hartmann Comment On Regulatory Notice 22-08
Kim Priem Comment On Regulatory Notice 22-08
Lapyin Chan Comment On Regulatory Notice 22-08
Brian Hutchinson Comment On Regulatory Notice 22-08
Daniel Villarosa Comment On Regulatory Notice 22-08
Sharon Lesch Comment On Regulatory Notice 22-08
Mark Conley Comment On Regulatory Notice 22-08
William Wilson Comment On Regulatory Notice 22-08
Jeff Brady Comment On Regulatory Notice 22-08
James G Comment On Regulatory Notice 22-08
Greg Schow Comment On Regulatory Notice 22-08
David Broockman Comment On Regulatory Notice 22-08
Kevan Prati Comment On Regulatory Notice 22-08
Jeffrey Brumitt Comment On Regulatory Notice 22-08
Mariya Gviazda Comment On Regulatory Notice 22-08
Mark McCall Comment On Regulatory Notice 22-08
Albert Tagg Comment On Regulatory Notice 22-08
Anthony Tiliacos Comment On Regulatory Notice 22-08
Walter Krouson Comment On Regulatory Notice 22-08
Craig Rager Comment On Regulatory Notice 22-08
Arash Zolghadr Comment On Regulatory Notice 22-08
Ken Peters Comment On Regulatory Notice 22-08
Kenneth Bauman Comment On Regulatory Notice 22-08
Wesley Mah Comment On Regulatory Notice 22-08
Paige Formicone Comment On Regulatory Notice 22-08
Aarthur Torquato Comment On Regulatory Notice 22-08
Scott Lopez Comment On Regulatory Notice 22-08
Tuan Vo Comment On Regulatory Notice 22-08
Norman Boldt Comment On Regulatory Notice 22-08
George Van Sickle Comment On Regulatory Notice 22-08
Marvenia Bosley Comment On Regulatory Notice 22-08
Robyn Im Comment On Regulatory Notice 22-08
Brandon Keehr Comment On Regulatory Notice 22-08
Brayden Misiolek Comment On Regulatory Notice 22-08
Glenn Cedotal Comment On Regulatory Notice 22-08
John Lago Comment On Regulatory Notice 22-08
Matthew Simons Comment On Regulatory Notice 22-08
Manoj Ravuru Comment On Regulatory Notice 22-08
Ariel Wainer Comment On Regulatory Notice 22-08
Ralph Ginese Comment On Regulatory Notice 22-08
Bryce Goldstein Comment On Regulatory Notice 22-08
Sibbett Sapp Comment On Regulatory Notice 22-08
Adam DeLong Comment On Regulatory Notice 22-08
Roger Xie Comment On Regulatory Notice 22-08
Jennifer Pollack Comment On Regulatory Notice 22-08
Douglas Hoen Comment On Regulatory Notice 22-08
David Robbins Comment On Regulatory Notice 22-08
Hans Negd Comment On Regulatory Notice 22-08
John McColgan Comment On Regulatory Notice 22-08
Lee Schloss Comment On Regulatory Notice 22-08
John Freed Comment On Regulatory Notice 22-08
Andrew Gargus Comment On Regulatory Notice 22-08
Carey Moulton Comment On Regulatory Notice 22-08
Erik Midelfort Comment On Regulatory Notice 22-08
Nathan Lindberg Comment On Regulatory Notice 22-08
Jared Maltbie Comment On Regulatory Notice 22-08
Scott Wolf Comment On Regulatory Notice 22-08
Matthew Worden Comment On Regulatory Notice 22-08
Lillian Ruiz Comment On Regulatory Notice 22-08
Jens Pilegaard Comment On Regulatory Notice 22-08
Jennifer Drown Comment On Regulatory Notice 22-08
Michael Dammen Comment On Regulatory Notice 22-08
Kumar Kumarachandran Comment On Regulatory Notice 22-08
Cameron Morris Comment On Regulatory Notice 22-08
Andrew Parker Comment On Regulatory Notice 22-08
John Starke Comment On Regulatory Notice 22-08
Matthew Contreras Comment On Regulatory Notice 22-08
Simon Assaad Comment On Regulatory Notice 22-08
Stephen Power Comment On Regulatory Notice 22-08
Ken McDevitt Comment On Regulatory Notice 22-08
Terry Neal Comment On Regulatory Notice 22-08
Robert Stevens Comment On Regulatory Notice 22-08
Dan Townsend Comment On Regulatory Notice 22-08
Alfred Hencken Comment On Regulatory Notice 22-08
Robert Prouty Comment On Regulatory Notice 22-08
James Wilcox Comment On Regulatory Notice 22-08
Russ Dijak Comment On Regulatory Notice 22-08
Carol Holman Comment On Regulatory Notice 22-08
Jesse Lavender Comment On Regulatory Notice 22-08
Jack Hayes Comment On Regulatory Notice 22-08
Michele Nicastro Comment On Regulatory Notice 22-08
Vera Plechash Comment On Regulatory Notice 22-08
Ming Liu Comment On Regulatory Notice 22-08
Robert Hall Comment On Regulatory Notice 22-08
Robert Vidal Comment On Regulatory Notice 22-08
Hien Nguyen Comment On Regulatory Notice 22-08
James Salvo Comment On Regulatory Notice 22-08
Leslie Davis Comment On Regulatory Notice 22-08
Matthew Scheflen Comment On Regulatory Notice 22-08
John McAuliffe Comment On Regulatory Notice 22-08
Rafal Kuczawski Comment On Regulatory Notice 22-08
John Pietsch Comment On Regulatory Notice 22-08
James Tracy Comment On Regulatory Notice 22-08
John Russell Comment On Regulatory Notice 22-08
Adam Tuton Comment On Regulatory Notice 22-08
Jay Weiss Comment On Regulatory Notice 22-08
Michael Hallberg Comment On Regulatory Notice 22-08
Christopher Rudat Comment On Regulatory Notice 22-08
Carl Moore Comment On Regulatory Notice 22-08
Barbara Jencik Comment On Regulatory Notice 22-08
George Jones Comment On Regulatory Notice 22-08
Zev Abraham Comment On Regulatory Notice 22-08
Chenwei Ni Comment On Regulatory Notice 22-08
Mohammad Jarrad Comment On Regulatory Notice 22-08
Sari Marks Comment On Regulatory Notice 22-08
William Arnold Comment On Regulatory Notice 22-08
Christopher Polson Comment On Regulatory Notice 22-08
Jerald Vegwert Comment On Regulatory Notice 22-08
Michael Dew Comment On Regulatory Notice 22-08
Belal Farouk Comment On Regulatory Notice 22-08
Anthony Parrish Comment On Regulatory Notice 22-08
Lap Chan Comment On Regulatory Notice 22-08
Randall Guess Comment On Regulatory Notice 22-08
Chad Koepke Comment On Regulatory Notice 22-08
Taylor Larsen Comment On Regulatory Notice 22-08
Marshall Hechter Comment On Regulatory Notice 22-08
Dave Gillespie Comment On Regulatory Notice 22-08
Russell Laux Comment On Regulatory Notice 22-08
Innesa Shinkarsky Comment On Regulatory Notice 22-08
Bruce Winans Comment On Regulatory Notice 22-08
Kannan Chandran Comment On Regulatory Notice 22-08
Jalen Johnson Comment On Regulatory Notice 22-08
Lawrence Chi Comment On Regulatory Notice 22-08
Bharat Rudrakshala Comment On Regulatory Notice 22-08
Thomas Basso Comment On Regulatory Notice 22-08
Dale Neaderhouser Comment On Regulatory Notice 22-08
Yuk Wong Comment On Regulatory Notice 22-08
Bruce Taylor Comment On Regulatory Notice 22-08
Max Mitchell Comment On Regulatory Notice 22-08
Clarence Gilstad Comment On Regulatory Notice 22-08
John Braund Comment On Regulatory Notice 22-08
Rahul Poonekar Comment On Regulatory Notice 22-08
Amine Fehmi Comment On Regulatory Notice 22-08
Frey Zhou Comment On Regulatory Notice 22-08
Dominik Sarna Comment On Regulatory Notice 22-08
Matthew Dennis Comment On Regulatory Notice 22-08
David Kalitowski Comment On Regulatory Notice 22-08
Faith Rendell Comment On Regulatory Notice 22-08
Alastair Gregory Comment On Regulatory Notice 22-08
Katherine Geeslin Comment On Regulatory Notice 22-08
Craig Watel Comment On Regulatory Notice 22-08
Frank Simons Comment On Regulatory Notice 22-08
Ron Kirby Comment On Regulatory Notice 22-08
Thomas Williams Comment On Regulatory Notice 22-08
David Hunt Comment On Regulatory Notice 22-08
Richard Devin Comment On Regulatory Notice 22-08
Dale Reed Comment On Regulatory Notice 22-08
Barry Hall Comment On Regulatory Notice 22-08
Donald Downs Comment On Regulatory Notice 22-08
Dajen Huang Comment On Regulatory Notice 22-08
Scott Moore Comment On Regulatory Notice 22-08
Donald Jackson Comment On Regulatory Notice 22-08
James Hamilton Comment On Regulatory Notice 22-08
Yu Kim Comment On Regulatory Notice 22-08
Dan Tharp Comment On Regulatory Notice 22-08
Neill Carson Comment On Regulatory Notice 22-08
Frank Fetzer Comment On Regulatory Notice 22-08
Donald Wallens Comment On Regulatory Notice 22-08
Joel Mitchell Comment On Regulatory Notice 22-08
Robert Tanner Comment On Regulatory Notice 22-08
Randy O'Dell Comment On Regulatory Notice 22-08
Jay Robinson Comment On Regulatory Notice 22-08
Glenn Thach Comment On Regulatory Notice 22-08
John Marinaro Comment On Regulatory Notice 22-08
Ryan L'Amoreaux Comment On Regulatory Notice 22-08
Kyle Druskin Comment On Regulatory Notice 22-08
Gregory Lentz Comment On Regulatory Notice 22-08
Michael Lippman Comment On Regulatory Notice 22-08
Shawn Warren Comment On Regulatory Notice 22-08
Terrence Anderson Comment On Regulatory Notice 22-08
Robert Cassa Comment On Regulatory Notice 22-08
Michael Cruz Comment On Regulatory Notice 22-08
Craig Boyer Comment On Regulatory Notice 22-08
Nathalie Bijlsma Comment On Regulatory Notice 22-08
Gary Ozga Comment On Regulatory Notice 22-08
Justin Todd Comment On Regulatory Notice 22-08
Craig Miller Comment On Regulatory Notice 22-08
Ronald Gadek Comment On Regulatory Notice 22-08
Richard Stevens Comment On Regulatory Notice 22-08
Ann Carey Comment On Regulatory Notice 22-08
Tyler Davidson Comment On Regulatory Notice 22-08
Stephen Smith Comment On Regulatory Notice 22-08
James Long Comment On Regulatory Notice 22-08
Anil Samuel Comment On Regulatory Notice 22-08
Kenneth Fry Comment On Regulatory Notice 22-08
Bernard Dalsey Comment On Regulatory Notice 22-08
John Carroll Comment On Regulatory Notice 22-08
Mary Pastore Comment On Regulatory Notice 22-08
Nicolas Amaro Comment On Regulatory Notice 22-08
Tim Raburn Comment On Regulatory Notice 22-08
Tom Watts Comment On Regulatory Notice 22-08
Mark Kuklis Comment On Regulatory Notice 22-08
Jose Sanchez Comment On Regulatory Notice 22-08
Stanley Partyka Comment On Regulatory Notice 22-08
Matthew Thornton Comment On Regulatory Notice 22-08
Garrett LaRue Comment On Regulatory Notice 22-08
Quang Nguyen Comment On Regulatory Notice 22-08
Virginia King Comment On Regulatory Notice 22-08
Billy Hallmon Comment On Regulatory Notice 22-08
Mark Buel Comment On Regulatory Notice 22-08
Shannon Woods Comment On Regulatory Notice 22-08
Daniel Pearson Comment On Regulatory Notice 22-08
William Scarcella Comment On Regulatory Notice 22-08
Donald Lange Comment On Regulatory Notice 22-08
Nick Difazio Comment On Regulatory Notice 22-08
Derek Tonn Comment On Regulatory Notice 22-08
Owen Z Comment On Regulatory Notice 22-08
Warren Shepherd Comment On Regulatory Notice 22-08
Bill Davenport Comment On Regulatory Notice 22-08
Richard Torres Comment On Regulatory Notice 22-08
Eric Eiden Comment On Regulatory Notice 22-08
Willman Gonzalez Comment On Regulatory Notice 22-08
A.D. Roberts Comment On Regulatory Notice 22-08
David Son Comment On Regulatory Notice 22-08
Radley Little Comment On Regulatory Notice 22-08
Jon Gray Comment On Regulatory Notice 22-08
David Son Comment On Regulatory Notice 22-08
Randall Gremp Comment On Regulatory Notice 22-08
Jungshik Kang Comment On Regulatory Notice 22-08
Marsha Adams Comment On Regulatory Notice 22-08
Steve Mudge Comment On Regulatory Notice 22-08
Milton McKinney Comment On Regulatory Notice 22-08
Ken Wang Comment On Regulatory Notice 22-08
James Robson Comment On Regulatory Notice 22-08
Frank Hellman Comment On Regulatory Notice 22-08
Jeffrey Schroeder Comment On Regulatory Notice 22-08
Christian Rocklein Comment On Regulatory Notice 22-08
Donald Staker Comment On Regulatory Notice 22-08
Ryan Joyce Comment On Regulatory Notice 22-08
Chaithanya Vatti Comment On Regulatory Notice 22-08
Kyle Eley Comment On Regulatory Notice 22-08
Raz Goldin Comment On Regulatory Notice 22-08
Jeffrey Junig Comment On Regulatory Notice 22-08
Jay Past Comment On Regulatory Notice 22-08
David Harlan Comment On Regulatory Notice 22-08
Adam Hubbartt Comment On Regulatory Notice 22-08
Robert Silver Comment On Regulatory Notice 22-08
Alberto Gutierrez Comment On Regulatory Notice 22-08
George Alexander Comment On Regulatory Notice 22-08
Malik Barbarawi Comment On Regulatory Notice 22-08
Terry Neal Comment On Regulatory Notice 22-08
Robert Rios Comment On Regulatory Notice 22-08
Kenneth Gobart Comment On Regulatory Notice 22-08
Trevor Casper Comment On Regulatory Notice 22-08
Jeremy Fish Comment On Regulatory Notice 22-08
Juan Garcia Comment On Regulatory Notice 22-08
Michael Cosgrove Comment On Regulatory Notice 22-08
Mike Hahne Comment On Regulatory Notice 22-08
Brenda Robertson Comment On Regulatory Notice 22-08
Mark Lynch Comment On Regulatory Notice 22-08
Andreas Montes Comment On Regulatory Notice 22-08
Derek Barnett Comment On Regulatory Notice 22-08
Ryan Kristek Comment On Regulatory Notice 22-08
Greg Fuller Comment On Regulatory Notice 22-08
Brian Leschorn Comment On Regulatory Notice 22-08
Kulin Boda Comment On Regulatory Notice 22-08
Worrell Couto Comment On Regulatory Notice 22-08
Sean O'Brien Comment On Regulatory Notice 22-08
Noam Mishkoff Comment On Regulatory Notice 22-08
Prat Shar Comment On Regulatory Notice 22-08
Hongjian Yang Comment On Regulatory Notice 22-08
Hector Herrera Comment On Regulatory Notice 22-08
Barry Campbell Comment On Regulatory Notice 22-08
Joshua Hykes Comment On Regulatory Notice 22-08
Thomas Fischetti Comment On Regulatory Notice 22-08
John Rogers Comment On Regulatory Notice 22-08
Zachary Shelton Comment On Regulatory Notice 22-08
Douglas Sweeney Comment On Regulatory Notice 22-08
Ronald Swalboski Comment On Regulatory Notice 22-08
Peter Obermeyer Comment On Regulatory Notice 22-08
Kirk Bitu Comment On Regulatory Notice 22-08
Edward Lundeen Comment On Regulatory Notice 22-08
Serge Korovitsyn Comment On Regulatory Notice 22-08
Ryan Martinez Comment On Regulatory Notice 22-08
Gerald Shugart Comment On Regulatory Notice 22-08
Christy Conrad Comment On Regulatory Notice 22-08
Ricardo Quintero Comment On Regulatory Notice 22-08
Ronald Sanderson Comment On Regulatory Notice 22-08
Kevin Pattison Comment On Regulatory Notice 22-08
Gary Tharalson Comment On Regulatory Notice 22-08
Rick Muller Comment On Regulatory Notice 22-08
Ju Park Comment On Regulatory Notice 22-08
Austin Meservia Comment On Regulatory Notice 22-08
Alexander Heintz Comment On Regulatory Notice 22-08
Jimmy Forrest Comment On Regulatory Notice 22-08
Richard McCarthy Comment On Regulatory Notice 22-08
Thomas Grimme Comment On Regulatory Notice 22-08
Lynn Middelstadt Comment On Regulatory Notice 22-08
Robert Schweitzer Comment On Regulatory Notice 22-08
Brian Leahy Comment On Regulatory Notice 22-08
Terry Duke Comment On Regulatory Notice 22-08
Ryan Wessel Comment On Regulatory Notice 22-08
Susan Kemble Comment On Regulatory Notice 22-08
Joshua Moreno Comment On Regulatory Notice 22-08
David Wolfgang Comment On Regulatory Notice 22-08
Paul Belousov Comment On Regulatory Notice 22-08
Nathan Harvey Comment On Regulatory Notice 22-08
Herbert Michael Comment On Regulatory Notice 22-08
J Weil Comment On Regulatory Notice 22-08
Brian Burns Comment On Regulatory Notice 22-08
Niraj Varma Comment On Regulatory Notice 22-08
Robin Yiu Comment On Regulatory Notice 22-08
Stephen O'Connor Comment On Regulatory Notice 22-08
Steve Eidemiller Comment On Regulatory Notice 22-08
Paul LoMonaco Comment On Regulatory Notice 22-08
Michael Sciacca Comment On Regulatory Notice 22-08
John Roska Comment On Regulatory Notice 22-08
Mark Alkema Comment On Regulatory Notice 22-08
Christopher DeMois Comment On Regulatory Notice 22-08
George Noffs Comment On Regulatory Notice 22-08
Japheth Allison Comment On Regulatory Notice 22-08
David Bichler Comment On Regulatory Notice 22-08
Randolph Hurt Comment On Regulatory Notice 22-08
Gail Joseph Comment On Regulatory Notice 22-08
Kevin Nowell Comment On Regulatory Notice 22-08
Divy Srivastava Comment On Regulatory Notice 22-08
Michael Walsh Comment On Regulatory Notice 22-08
Adam Dings Comment On Regulatory Notice 22-08
Monte Cavasos Comment On Regulatory Notice 22-08
Bonnie Kuria Comment On Regulatory Notice 22-08
John Gertsch Comment On Regulatory Notice 22-08
Joohyun Jung Comment On Regulatory Notice 22-08
Paul Wood Comment On Regulatory Notice 22-08
Polly Fairchild Comment On Regulatory Notice 22-08
Robert Toben Comment On Regulatory Notice 22-08
Vince Vivirito Comment On Regulatory Notice 22-08
Ben Kovitz Comment On Regulatory Notice 22-08
Michael Lancaster Comment On Regulatory Notice 22-08
Maria Zempoalteca Comment On Regulatory Notice 22-08
Nikolas Petrakis Comment On Regulatory Notice 22-08
Jillian Dixon Comment On Regulatory Notice 22-08
Peter Roumanas Comment On Regulatory Notice 22-08